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Abstract 
Pituitary tumors usually show a particular benign nature, with a slow growth 
potential. Despite these characteristics, they can cause severe complications due 
to their excessive hormone secretion. Still, further investigations are needed to 
understand the molecular mechanisms implicated in their development in detail. 
AHRR (Aryl Hydrocarbon Receptor (AHR) Repressor) and HSP90 (Heat Shock 
Protein 90) are good candidates for playing a role in pituitary tumorigenesis due to 
their tumorigenic role reported in different types of tumors and their action in the 
metabolism of endocrine disruptors (EDs), in which AIP (Aryl Hydrocarbon Receptor 
Interacting Protein) is also implicated. AHR Repressor (AHRR) is the main regulator 
of AHR activity through a negative feedback mechanism, which impairment leads to 
tumor-promoting events. Accordingly, AHRR downregulation was reported in 
several malignancies including colon, breast and lung cancer and was correlated 
with a more malignant phenotype (e.g. resistance to apoptosis, increased cellular 
motility and angiogenic potential) in different tumor cell lines. Although several 
studies investigated the potential role of AHR signaling in pituitary tumorigenesis, 
so far no data has been available on the role of AHRR in pituitary tumorigenesis. 
Therefore, the primary aim of the present study was to evaluate the possible role of 
AHRR in influencing the tumor phenotype in the somato-lactotroph cell line GH3 in 
which AHRR was stably silenced or overexpressed. AHRR-silenced cells showed a 
less aggressive phenotype due to a decreased cell viability and to a more 
pronounced resistance to apoptosis-inducing stimulus in comparison to the control. 
Correspondingly, opposite results were obtained for the stable overexpression of 
AHRR. In addition, AHRR silencing increased senescence-associated beta 
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galactosidase (SA-β Gal) staining in accordance with a slow-growing phenotype 
observed at proliferation level, without having effect on cell cycle progression. No 
correlation was observed between AHRR mRNA expression in human pituitary 
adenomas and tumor aggressiveness, although GH-secreting tumors displayed a 
higher expression of AHRR in comparison to normal pituitaries.  
The second part of this thesis was aimed at the role of HSP90 in the pathogenesis 
of GH-secreting tumors. In addition to the stabilization of AHR, this protein plays a 
pivotal role in maturation and stabilization of other proteins implicated in oncogenic 
signaling and cancer progression, and treatment with HSP90 inhibitors has recently 
shown promising results in pituitary corticotroph adenomas. Therefore, the function 
of HSP90 was investigated in GH-secreting pituitary adenomas. An intense HSP90 
immunoreactivity was reported in 8 out of 25 GH-secreting pituitary tumors. In order 
to study the therapeutic potential of HSP90 inhibition in these tumors, the cell line 
GH3 was treated with different HSP90 inhibitors. The C-terminal HSP90 inhibitors 
novobiocin and KU174 dose-dependently decreased GH promoter activity, whereas 
only KU174 decreased GH secretory levels.  
Conclusively, the data presented herein provide novel insights in the pathogenesis 
of GH-secreting pituitary adenomas. AHRR might have an oncogenic role by 
influencing tumor aggressiveness, as shown in the cellular model. Moreover, the 
results obtained in the second part suggest that HSP90 might have a role in the 
tumorigenesis of GH-secreting pituitary tumors and a potential for HSP90 C-terminal 
inhibitors in managing the excess of GH secretion. 
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Riassunto 
I tumori ipofisari manifestano normalmente un fenotipo benigno, caratterizzato da 
un potenziale di crescita ridotto. Anche in assenza di effetti patogenetici dovuti 
all´espansione della massa tumorale nelle strutture adiacenti, possono causare 
severe complicazioni a causa della loro eccessiva secrezione ormonale. Studi 
approfonditi sono ancora necessari per riconoscere nuovi meccanismi molecolari 
implicati nel loro sviluppo. AHRR (Aryl Hydrocarbon Receptor (AHR) Repressor) e 
HSP90 (Heat Shock Protein 90), oltre ad avere un ruolo nella tumorigenesi in tessuti 
di differente origine, potrebbero potenzialmente essere coinvolti nello sviluppo dei 
tumori ipofisari per via della loro attività nel metabolismo di Endocrine Disruptors 
(EDs), in cui anche la proteina AIP (Aryl Hydrocarbon Receptor Interacting Protein) 
è implicata. AHRR é il principale regolatore dell’attività di AHR, e lo sbilanciamento 
di questo sistema di regolazione può avere effetti tumorigenici. Nella fattispecie, 
l´espressione ridotta di AHRR è stata descritta in tumori di differente origine 
anatomica tra i quali colon, seno e polmone; e sembra essere associata ad una 
maggiore aggressività del fenotipo tumorale (in termini di resistenza all´apoptosi, 
aumento della proliferazione e potenziale angiogenico) in differenti modelli cellulari. 
Nonostante diversi studi abbiano investigato il potenziale ruolo della via di segnale 
di AHR nei tumori ipofisari, non vi sono evidenze riguardo al ruolo specifico di 
AHRR. Scopo principale di questo lavoro di tesi è stato perciò valutare il possibile 
ruolo di AHRR nella patogenesi dei tumori ipofisari. La linea cellulare somato-
lattotropa GH3 è stata utilizzata come modello per generare cloni stabili in cui AHRR 
è silenziato o overespresso. Il silenziamento di AHRR ha portato alla manifestazione 
di un fenotipo meno aggressivo dovuto alla diminuzione della capacità proliferativa 
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e alla maggiore resistenza a stimoli apoptotici rispetto al controllo, mentre risultati 
opposti sono stati ottenuti overesprimendo stabilmente AHRR. È stato inoltre 
evidenziato come il silenziamento di AHRR abbia indotto la manifestazione di un 
fenotipo più senescente rispetto al controllo, in correlazione con la riduzione della 
proliferazione cellulare. Non sembra però che ciò coinvolga un cambiamento sulla 
distribuzione del ciclo cellulare. Inoltre, forse a causa del numero ridotto di campioni 
analizzati, la valutazione quantitativa dell’espressione a livello dell’mRNA di AHRR 
nei tumori ipofisari non sembra essere in relazione con l’aggressività tumorale, 
anche se nel sottogruppo adenomi GH-secernenti vi sia una maggiore espressione 
rispetto a campioni di ipofisi normali. 
La seconda parte di questo lavoro di tesi ha avuto come scopo la valutazione del 
ruolo di HSP90 nella patogenesi dei tumori ipofisari. Oltre alla stabilizzazione di 
AHR, questa proteina svolge un ruolo fondamentale nella maturazione e nella 
stabilizzazione di altre proteine implicate nella trasformazione e nella progressione 
tumorale, e la sua inibizione specifica ha recentemente dimostrato risultati 
promettenti negli adenomi ACTH-secernenti. Sulla base di queste premesse, la 
valutazione del ruolo di HSP90 è stata estesa ai tumori GH-secernenti. L´analisi 
immunoistochimica effettuata su adenomi GH secernenti ha evidenziato una 
intensa immunoreattivitá di HSP90 in 8/25 casi. Visto il potenziale coinvolgimento 
di HSP90 in questa tipologia di adenomi ipofisari, la linea cellulare GH3 è stata 
utilizzata come modello per investigare il potenziale terapeutico di differenti inibitori 
di HSP90. Nella fattispecie, il trattamento con gli inibitori C-terminali di HSP90 
novobiocina e KU174 ha provocato una diminuzione dose-dipendente dell´attivitá 
promotoriale del GH, mentre solo KU174 ha significativamente diminuito la 
secrezione di GH.  
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In conclusione, i risultati ottenuti forniscono evidenze funzionali sul possibile ruolo 
oncogenico di AHRR nell´ipofisi, influendo sul fenotipo aggressivo nel modello 
cellulare utilizzato. Abbiamo inoltre dimostrato il potenziale ruolo di HSP90 nella 
patogenesi dei tumori ipofisari GH-secernenti, e il trattamento con inibitori C-
terminali di HSP90 potrebbe risultare efficace nel diminuire l´eccessiva produzione 
e secrezione di GH.  
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1. Introduction 
1.1 The pituitary gland 
1.1.1 Anatomy 
The pituitary gland is one of the master regulators of the endocrine system, including 
the thyroid gland, adrenal glands, ovaries and testes under its control. It situates in 
the sella turcica of the sphenoid, below the optic chiasma, and is connected with the 
tuber cinereum of the hypothalamus through the pituitary peduncle. The pituitary 
gland consists of two major parts fused together, but with different functions, the 
adenohypohysis and the neurohyphophysis, both connected to different neuro-
secreting regions of the hypothalamus1 (Figure 1.1). The neurohyphophysis is of 
neuro-ectodermic origin and is formed by the pituitary peduncle and the posterior 
lobe. The peduncle is constituted of the median eminence (or infundibulum) and the 
infundibular trunk. The posterior lobe contains pituicytes, specialized glial cells 
assisting in the storage and release of the hormones1. The adenohyphophysis is of 
ectodermic origin and is divided in the anterior lobe, and in the intermediate lobe, 
very reduced in mature human pituitary gland in compared to in human fetus or most 
animals. The anterior lobe is made of a highly vascularized stromal layer, in which 
parenchimal and endcorine epitelial cells are included. Specialized cells of the 
pituitary, especially in the adenohyphophysis, produce and secrete different 
hormones, from which these cells take their names1: 
-somatotroph cells, producing the somatotroph hormone or growth hormone (GH), 
which acts on metabolism and cellular division or stimulation of the liver production 
of insulin-like growth factor-1 (IGF-1), causing a general increase in the dimensions 
of the organism; 
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-adrenocorticotroph cells, producing the adrenocorticotroph hormone (ACTH), 
which among multiple other roles stimulate the secretion of cortisol from the adrenal 
cortex; 
-lactotroph cells, producing the lactrotroph hormone or prolactin (PRL), controlling 
mammary development, which among others regulate the action of gonadotropins 
on their target organs in men and women. 
-gonadotroph cells, producing gonadotropins (folicule-stimulating hormone, FSH, 
and luteinising hormone, LH), which act in the development of gonads in women 
and men; 
-tireotroph cells, producing the thyroid-stimulating hormone (TSH), which stimulates 
the secretion of thyroid hormones1. 
-cells from the neurohyphophysis in the posterior lobe secreting oxytocin and 
vasopressin or antidiuretic hormone (ADH), which are produced in the neuro-
secreting neurons of the supraoptic and paraventricular nuclei of the hypothalamus. 
These hormones stimulate the contraction of the muscles of the uterus during and 
after the delivery and the reabsorption of water in the distal and collecting ducts of 
the kidney respectively2,3. 
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Figure 1.1: Schematic representation of the pituitary gland. Adapted from 
https://sites.google.com/a/wisc.edu/neuroradiology/anatomy4. 
1.1.2 Regulation of hormone secretion 
Pituitary hormone secretion is regulated through three different levels of control. 
Hypothalamic control is mediated by adenohyphophisiotropic hormones secreted 
into the portal system that impact on anterior pituitary cell surface receptors, which 
are G protein-coupled receptors (GPCRs) specific for releasing and inhibiting 
hormones. Peripheral hormones also participate in mediating pituitary function, 
mainly through negative feedback regulation of trophic hormones by their respective 
target hormones. Intrapituitary paracrine and autocrine factors like cytokines or 
growth factors are also acting for regulating pituitary cells development and function. 
The result of the regulation of this complex system is the temporal control of the 
secretion of the pituitary hormones (ACTH, GH, PRL, TSH, FSH and LH) through 
the cavernous sinus, the petrosal veins and the systemic circulation (Figure 1.2)5. 
Because most data concern acromegaly in this thesis, the next paragraphs will be 
focused on the regulation of GH and PRL synthesis. 
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Figure 1.2: Regulation of anterior pituitary hormone secretion at different levels. Level I: 
Hypothalamic hormones impact on the receptors on the respective target cells. Level II: Intrapituitary 
growth factors and cytokines regulate differentiation and function of pituitary cells by paracrine and 
(autocrine) action. Level III: Peripheral hormones exert negative feedback inhibition of synthesis and 
secretion of pituitary hormones. CNS: central nervous system. Adapted from Ray et al., 1997 and 
Melmed et al., 20015,6. 
1.1.2.1 Regulation of GH synthesis 
GH has a pivotal role in the organism in promoting organ and soft tissue growth. It 
is secreted by somatotroph cells within the lateral wings of the anterior pituitary 
gland, and its synthesis is controlled by a complex regulatory mechanism. GH 
production and secretion is regulated by hypothalamic growth-hormone-releasing 
hormone (GHRH), ghrelin and somatostatin; IGF-1 inhibits GH secretion by a direct 
effect on the somatotroph cells and indirectly by stimulating the expression of 
somatostatin, which in turn inhibits GH secretion7,8.The expression of the GH gene 
is mainly controlled by a process in which elevated intracellular levels of cyclic 
adenosine monophosphate (cAMP) activate protein kinase A (PKA) 9,10. In the 
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human GH promoter there are two cAMP-responsive elements (CREs); moreover, 
in the promoter region of the gene there are two sites for the POU domain, class 1, 
transcription factor 1 (PIT-1); all of these sites are essential for cAMP 
responsiveness and for GH promoter activity in vitro and in vivo11–13. When secreted 
and bound to its specific receptor, GH exerts some of its physiological effects by 
activating the MAPK/ERK pathway and JAK-STAT pathway14. 
1.1.2.2 Regulation of PRL synthesis 
Prolactin is synthetized and secreted by lactotroph cells of the anterior pituitary 
gland. Primarily known for its role in enabling mammals, usually females, to produce 
milk, it also controls a variety of behaviors and even plays a role in homeostasis15. 
Transcription of the PRL gene is regulated by two independent promoter regions, 
consisting in one that directs the pituitary-specific expression and another one, more 
upstream, that is responsible for extrapituitary expression. Its secretion is regulated 
by endocrine neurons in the hypothalamus16; among these, a very important role is 
exerted by dopamine, which inhibits the basal high-secretory tone of lacotroph 
cells17. When synthetized, prolactin interacts with specific receptors present in 
mammary glands, ovaries, pituitary glands, heart, lung, thymus, spleen, liver, 
pancreas, kidney, adrenal gland, uterus, skeletal muscle, skin, and areas of the 
central nervous system. Binding with the receptor causes its dimerization, resulting 
in the activation of the mitogen-activated-protein kinases (MAPK) pathway, the Src 
kinase and the JAK-STAT pathway18. 
1.2 Pituitary Tumors 
Pituitary tumors comprehend nearly 15% of intracranial neoplasms19. They can 
arise from each type of hormone-secreting cells of the adenohyphophysis, and the 
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majority of them are of monoclonal origin. Their typical hallmarks are excessive 
cellular proliferation and over-secretion of their respective hormones, but they can 
also be functionally silent5. Although generically classified as benign, they can cause 
severe health complications due to the aberrant hormone secretion and the invasion 
of surrounding structures20. 
1.2.1 Classification of pituitary tumors 
Pituitary tumors are classified according to: a) the clinical manifestation of the 
hormonal activity in vivo; b) immunohistological hormone staining; and c) tumor size 
and degree of local invasion. The most recent update on the classification of pituitary 
tumors dates to the World Health Organization (WHO) Classification of 2004, in 
which novel putative oncogenes and tumor suppressor genes have been identified 
and more pathological markers were postulated to predict the biological behavior of 
pituitary adenomas21,22.  
a) Clinical hormone-secreting types are generally classified as: 
 GH-secreting adenomas or somatotrophinomas 
 PRL-secreting adenomas or prolactinomas 
 GH-and PRL-secreting adenomas or mammosomatotroph adenomas 
 ACTH-secreting adenomas or corticotrophinomas 
 TSH-secreting adenomas or thyrotrophinomas 
 FSH-and LH-secreting adenomas or gonadotrophinomas 
 Non-functioning adenomas (NFPAs). 
PRL-secreting adenomas have the highest prevalence (40-45%) among all types of 
pituitary tumors. Lesser common types of pituitary adenomas are in decreasing 
order NFPAs (30%), somatotrophinomas (15-20%), corticotrophinomas (5-15%), 
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thyrotrophinomas and FSH-LH adenomas (<1%)23–25. Mixed types of tumors can 
also occur, the most common combination being GH and PRL (5.2%)21,26,27. 
b) Histological classification distinguishes the different types of pituitary 
adenomas according to their reaction to staining into: 
 acidophilic (GH and/or PRL-producing tumors) 
 basophilic (ACTH, TSH and FSH/LH secreting tumors) 
 chromophobic (hormonally inactive tumors). 
 
c) The classification of tumors according to size and invasion classifies pituitary 
tumors in different grades: 
 Grade I refers to microadenomas, with diameter <10mm and contained in 
the pituitary fossa 
 Grade II refers to macroadenomas, with diameter >10mm that may have 
suprasellar extension but no invasion in the surrounding structures 
 Grade III for locally invasive tumors 
 Grade IV refers to large invasive tumors that can involve the 
hypothalamus and cavernous sinuses. 
1.2.1.1 Aggressive pituitary adenomas 
Pituitary tumors are generally benign and non-invasive. A significant number of 
pituitary tumors (between 45 and 55%) display features of invasiveness while 
maintaining benign behavior28. Pituitary tumors are defined as malignant (pituitary 
carcinomas) when showing cerebrospinal or systemic metastasis; they are rare, with 
an incidence of 0.2% of symptomatic pituitary tumors28. Aggressive pituitary tumors 
take their place between benign and malignant adenomas with a rather distinct 
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clinical behavior, invasion of the anatomical structures surrounding the pituitary, 
tendency to whitstand medical treatment and early postoperative recurrence29. In 
2004 the WHO published a novel classification system for pituitary tumors based 
upon immunohistochemistry for the detection of secretory products and other 
ultrastructural features. The term “atypical tumors” was introduced in this 
categorization. It includes tumors with “atypical” morphological features suggestive 
of an “aggressive behavior”, substantiated by the presence of invasive growth, high 
mitotic index, a Ki67 labelling index >3% and extensive nuclear staining for p5330. 
This classification is the first attempt at identifying tumors with a distinctive behavior 
compared to benign pituitary adenomas, but it displays an important weak spot by 
lacking clear consensus regarding the definition of invasive growth31. Due to the lack 
of a clear consensus on pituitary tumor aggressiveness, a small spotlight is put on 
histological and radiological parameters in the next paragraphs. 
1.2.1.1.1 Histological parameters: MIB-1 and p53 IHC staining 
The histological parameters for identifying the behavior of pituitary tumors take into 
account different factors that play a role in proliferation of pituitary tumor cells. MIB-
1 monoclonal antibody is the most commonly used one for the detection of Ki67 
staining and evaluation in paraffin-embedded tissue specimens of pituitary 
adenomas, with a reasonable correlation with pituitary adenomas growth rate32,33. 
High levels of the tumor suppressor p53 have been found in many cancers and have 
been considered as a marker for tumor atypicalness in the pituitary. However, there 
is still some debate about the value of these markers as predictors of aggressive 
behavior of pituitary adenomas in daily practice. Those tumors that exceed the WHO 
cut-offs for Ki67 labelling index and present intense immunoreactivity for p53 are 
uncommon even in tumors with postsurgical progression, and there is no clear 
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correlation between immunohistochemical p53 overexpression and progression of 
pituitary adenomas34,35. 
1.2.1.1.2 Radiological parameters: invasion of the surrounding areas 
While the classification of “atypical” pituitary adenomas mainly refers to histological 
markers, the term “aggressive” is not yet well defined for these types of tumors. 
Considering that an aspect of aggressiveness is the invasion into surrounding 
anatomical structures, the terms “aggressive” and “invasive” have been used 
interchangeably in literature. Great variation can also be found in the definition of 
pituitary invasiveness based on imaging features, histological proof of sphenoid 
sinus mucosal invasion and/ or intraoperative findings36. Furthermore, the precise 
anatomical structure infiltrated is of importance since invasion into different areas is 
not always indicative of aggressive behavior37. The application of Knosp’s and 
Hardy’s radiological classifications provides a useful tool for evaluating the extent 
and type of the invasion in pituitary tumors but is missing a correlation with the 
clinical course that could shed light on their aggressiveness38,39. A possible solution 
for this problem could consist in the combination of both proofs of invasiveness and 
histological findings40. 
1.2.2 Clinical manifestations of pituitary tumors 
Patients with pituitary tumors present a variety of signs and symptoms that can be 
generally divided into three categories: 
a) Signs and symptoms related to, or caused by, excessive hormone production 
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b) Signs and symptoms related to mechanical effects of the expansion of the 
tumor within the sella turcica, which could include visual disturbances and 
headaches 
c) Signs and symptoms of impaired normal pituitary function (partial-or 
panhypopituitarism). 
The following paragraphs will provide a brief description of the pathologic outcomes 
of pituitary adenomas, with particular attention to acromegaly. 
1.2.2.1 Acromegaly and gigantism 
The hallmark of acromegaly and gigantism is the presence of a chronic 
hypersecretion of GH and an excess of circulating IGF-1. Patients can be affected 
by acromegaly or gigantism depending on the age of onset of the disease: 
acromegaly has usually its manifestation in adults and gigantism in children. The 
etiology of the disease is usually a GH-secreting pituitary adenoma (>98%)41. 
Rarely, acromegaly may evolve due to hypothalamic tumor secreting GHRH or 
ectopic growth hormone releasing hormone secretion, or even more rarely due to 
GH from an ectopic source7. The incidence of acromegaly is about 3-4 cases per 
million, with a prevalence of 40-60 cases per million. No known sex, ethnic or racial 
differences are reported25,42. The peak incidence of the disease is around the fourth 
decade of life but patients may present with acromegaly at all ages43. Acromegaly 
is associated with a panel of different comorbidities. Although the over-secretion of 
GH can cause severe morbidities itself, most of the complications are due to the 
increased production of the GH-dependent factor IGF-1, synthetized in almost all 
body tissues, especially in the liver25. The disease is generally characterized by 
disproportionate skeletal, tissue and organ growth. At diagnosis (that usually occurs 
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when clinically obvious later stages are manifested, 5-10 years after the first 
symptoms) patients may present a wide range of clinical features which include 
skeletal and peripheral overgrowth and soft tissue enlargement with frontal bossing, 
mandibular prognathism, jaw malocclusion and overbite, skin thickening, as well as 
increased ring and shoe size44,45. Moreover, patients often present with several 
comorbidities including diabetes mellitus, headaches, visual symptoms, 
hypertension and other cardiovascular symptoms. Respiratory disorders can 
develop in acromegalic patients due to anatomical changes in the soft tissues and 
the craniofacial bone as well as alterations in the activity of respiratory muscles, 
which can lead to sleep apnea in up to 60% of cases46. Arthropathy affects nearly 
75% of patients with acromegaly and is the leading cause of functional disability in 
these patients47. Examination of data regarding cancer incidence in acromegalic 
patients showed a higher risk of developing colorectal cancer48. However, more 
recent studies from the German Acromegaly Registry did not show any indications 
for an association between acromegaly and the incidence of a particular type of 
cancer. All in all, the prolonged presence of some of the comorbidities leads to 
reduced life expectancy49. 
1.2.2.1.1 Medical management of Acromegaly 
Analysis of the principal causes of mortality in patients indicates that ~60% of 
acromegalic patients die from cardiovascular diseases, 25% from respiratory 
diseases and 15% from malignancies. In view of all of the adverse influences of 
GH/IGF-1 excess, treatment of all patients is indicated. Transphenoidal adenoctomy 
is usually considered as the treatment of choice. The main goals of the treatment 
are the reduction of GH values <2.5 μg/l and normalization of IGF-1 levels (adjusted 
for age and sex), preserving normal pituitary function and reversing the mechanical 
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effect of the tumor in the surrounding structures25,50. The adenoctomy, depending 
on tumor size and location, preoperative GH concentration and expertise of the 
surgeon, is usually successful in reaching these goals in 50% of the cases42 . 
Patients with residual tumor post-operatively or who are not good candidates for 
surgery require additional treatments for normalizing excessive GH secretion: these 
include radiotherapy and medical treatment. Radiotherapy can be effective in 
controlling tumor growth in 70-80% of patients, but hypopituitarism could arise in the 
long term period. Therefore, this treatment is generally regarded as third line option 
behind surgery and medical therapy51. The latter, is usually chosen to treat 
persistent or recurrent acromegaly after non-curative neurosurgery. Medical therapy 
can be also used as a primary therapy for patients in whom surgery is 
contraindicated or as a short-term therapy before the intervention23,52–54. 
Somatostatin Receptor Ligands (SRLs) were shown to effectively control GH 
excessive secretion in 50-70% of patients with partial amelioration of some of the 
co-morbidities55–57. Dopamine agonists were only effective in 10% of the patients 
and showed higher efficacy when combined with SRLs in presence of coexistent 
hyperprolactinemia, especially with long-acting treatments58–60. The GH-receptor 
antagonist pegvisomant was effective in normalizing IGF-1 levels in 67.5% of 
patients after 5 years of treatment. Due to the fact that it acts on target tissues for 
GH, it did not show to have an effect on tumor volume reduction7,52,61. The 
implementation of an efficient medical treatment is currently under development with 
the design of new therapeutic options which could improve the control of GH-and 
IGF-1 levels, reducing the impact of comorbidities that arise with the progression of 
the disorder7.  
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1.2.2.2 Hyperprolactinemia  
The symptoms of patients suffering from hyperprolactinemia may be due to the 
direct effects of excessive prolactin levels, the onset of galactorrhea or 
hypogonadism or the effects of the expanding mass of the pituitary tumor 
(headaches, visual defects). Affected women affected present with menstrual 
abnormalities, or regular cycles with infertility. Men present first present with 
symptoms related to the expansion of the pituitary tumor or adrenal/thyroid failure, 
although they may suffer from loss of libido or impotence for many years before the 
manifestation of the pituitary mass-related symptoms62.  
1.2.2.3 Cushing´s disease 
Cushing´s disease is characterized by high cortisol blood levels and loss of its 
circadian oscillation. Clinical symptoms usually vary depending on the duration and 
plasma levels of cortisol63; they may include obesity (centripetal fat deposition), 
signs of protein wasting (thin skin, abdominal purple to red and wide cutaneous 
striae, easy bruising), bone wasting leading to osteoporosis and possible fractures, 
hypertension, gonadal dysfunction and hyperandrogenism, as well as mild to severe 
psychic disturbances (depression, anxiety)64. 
1.2.2.4 Thyrotropinomas 
The adverse effects of TSH-secreting thyrotropinomas can be traced back to 
excessive levels of the hormone in the thyroid gland. Thyroid manifestations in 
patients with TSH-secreting adenomas include goiter, thyroid nodules and 
hyperthyroidism. Symptoms of mass effect like headaches and visual field defects 
also occur as most thyrotropinomas are macroadenomas at presentation65. 
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1.2.2.5 Gonadotropinomas 
Gonadotroph adenomas are difficult to diagnose because they are usually non-
secreting, or they secrete biologically inactive peptides with no clinical effects.  
Moreover, they usually grow silently until neurological symptoms develop. Clinical 
signs or symptoms of gonadotropin hypersecretion are very rarely reported, 
involving a few premenopausal women with ovarian hyperstimulation syndrome and 
men with macroorchidism66. 
1.2.2.6 NFPAs 
The category of NFPAs comprehends all the pituitary adenomas that are not 
hormonally active. At the present time, NFPAs are diagnosed either in the context 
of mass effect related to the expansion of a macroadenoma or during imaging for 
some unrelated purpose; the latter case is known as pituitary incidentaloma67. 
1.3 Pituitary tumorigenesis 
Pituitary tumorigenesis is a complex process in which intrinsic and extrinsic factors 
can participate. In fact, pituitary tumors may arise from alterations of pituitary cells 
or due to the dysregulation of regulatory factors like hypothalamic releasing and 
inhibitory hormones, peripheral hormones and paracrine growth factors. There are 
two main theories on pituitary tumorigenesis: the first implies a single mutational 
event in a single cell that will generate a monoclonal tumor, the second one asserts 
that the hypothalamus failing its regulatory role leads to a hyperplastic phenomenon 
in the target pituitary in which a mutational event provokes tumor formation. The 
monoclonal nature of the majority of pituitary tumors was elucidated by X-
chromosomal inactivation analysis in female patients68,69. This assumption was 
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confirmed by both loss of heterozygosity (LOH) analysis and X-chromosome 
inactivation, but it was also shown that recurrent tumors are frequently derived from 
independent clones of the initial tumor, indicating that there may be more than one 
clone, with one dominating the overall picture70. On the other side, there are several 
animal models providing support for the hypothesis that pituitary tumors develop 
from a background of hyperplasia of the respective cell type. Moreover, the 
importance of hypothalamic factors and peripheral hormones in influencing tumor 
growth and progression was supported by clinical findings71,72. 
In addition to their origin, another important aspect to consider for understanding the 
biology underlying pituitary tumorigenesis is cellular growth. In fact, a distinctive 
feature of pituitary tumors is their slow expansive growth that is associated with a 
benign nature of the tumor in the majority of cases, rarely progressing to 
carcinogenesis. Considering that benign tumors usually present a senescent-like 
phenotype that is not present in their malignant counterparts73, and that low pituitary 
tumor proliferative activity might be reflective of a proliferative arrest74, cellular 
senescence has been hypothesized to be a novel mechanism that could drive 
pituitary tumors development75, in a process that might involve alterations in gene 
expression. Thus, the following paragraph will provide an overall description of the 
genetic causations of pituitary tumors, with particular attention to pituitary 
senescence. 
1.3.1 The genetics of pituitary adenomas 
Pituitary tumors can occur because of the activation of proto-oncogenes or the 
inactivation of tumor-suppressor genes (TSGs), and by epigenetic mechanisms 
combining these two processes. Oncogenes are responsible for a gain of function 
and are dominant at cellular level, requiring a single "hit" in order to lead the cell to 
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tumorigenesis. Conversely, a TSG only loses its “anti-tumor protection” role only 
when both alleles are lost76. Oncogenes (RAS, MYC) and TSGs (p53, RB) mutations 
commonly encountered in non-endocrine neoplasms are rarely present in pituitary 
adenomas, but do occur in particularly aggressive tumors77,78. Several other genetic 
alterations have been implicated in pituitary tumorigenesis; that here are briefly 
listed and described here. 
Heterozygous activating somatic point mutations in the α-subunit of the stimulatory 
Gs protein (Gαs) were the earliest dominant activating mutations described in 
pituitary tumors. The activated oncogene stimulates proliferation and GH 
hypersecretion involving the activated form of the transcription factor cyclic AMP 
Response Element Binding Protein (CREB)79,80. The mammalian securin, known as 
Pituitary Tumor-Transforming gene (PTTG) is a proto-oncogene required for 
pituitary tumorigenesis; it induces tumor transformation when overexpressed and its 
levels correlate with tumor angiogenesis as well as to tumor invasiveness and 
aggressiveness81. Several conditions are associated with a known genetic defect 
predisposing to pituitary adenomas. These include multiple endocrine neoplasia 
type 1 (MEN1) and Carney complex (CNC), which are related to mutations of the 
TSG MEN1, and protein kinase A regulatory subunit-1-alpha (PRKAR1A), 
respectively82. Truncating mutations in the cyclin-dependent kinase inhibitor 1B 
(CDKN1B) gene or in its upstream open reading frame (uORF) defined susceptibility 
for a novel type of endocrine neoplasia termed MEN483–85. Mutations in the aryl 
hydrocarbon receptor interacting protein (AIP) gene are associated with a 
predisposition to pituitary adenoma formation86. McCune-Albright syndrome caused 
by activating mutations in the guanine nucleotide-activating alpha-subunit gene 
(GNAS), could lead to PA in a hereditary setting, but no familial cases have been 
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reported to date87,88. Recently, the duplication and a recurrent mutation of the G-
protein-coupled receptor 1 (GPR101) gene has been associated to the development 
of a new pituitary gigantism syndrome in young children called X-LAG acrogigantism 
(X-LAG)89. In addition, somatic mutations affecting the deubiquitinase gene USP8 
have been reported in a high percentage of ACTH-secreting pituitary adenomas90. 
Several other TSGs have been associated with pituitary tumorigenesis, but their 
abnormal expression was not reported in correlation with mutations: these include 
the zinc-finger protein pleomorphic adenoma gene-like 1 (ZAC)91, the Growth arrest 
and DNA damage-inducible protein gamma (GADD45G)92, and maternally 
expressed protein 3A (MEG3A)81,93. 
1.3.2 Pituitary senescence  
Pituitary adenomas very rarely progress to become true metastatic carcinomas and 
exhibit stable growth even after decades of observation94. Considering this usually 
low proliferation rate, senescence could be proposed as a candidate to explain the 
benign behavior of pituitary tumors. Cell cycle dysregulation was reported in pituitary 
adenomas, including overexpression of cyclins, and downregulation of cyclin-
dependent kinases and Retinoblastoma Protein (Rb) expression. The altered 
expression of cytokines and growth factors was also observed in pituitary tumors. 
In particular, IL-6, which has an important role in pituitary tumor progression, has 
been found to have a pivotal role in induction and maintenance of oncogene-induced 
senescence (OIS), suggesting its role as stimulator of adenoma progression 
inducing OIS95,96. The gene PTTG is correlated with invasiveness, recurrence, poor 
prognosis, and tumor metastasis97,98 and its overexpression is required for pituitary 
tumorigenesis99,100. PTTG deletion results in pituitary-specific senescent features, 
including upregulation of the cyclin-dependent kinases inhibitors p15INK4B, 
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p16INK4A, and p21CIP1, and hypophosphorylation of Rb97,98,101, overexpression of 
cyclin D1, apoptosis block, and elevated senescence-associated β-galactosidase 
(SA-β Gal) expression74,102,103. A representative illustration of model for the 
induction of cellular senescence during the development of pituitary adenomas is 
shown in Figure 1.3. 
 
Figure 1.3: Representative model of the induction of senescence during pituitary tumor 
development. The initial proliferative phase of pituitary tumors is followed by a “stoppage phase” 
due to cellular mechanism activated by OIS, resulting in a benign tumor with stable growth arrest. 
Adapted from Sapochnik et al., 2015103. 
1.4 AHR-HSP90-AIP complex 
The novel molecular mechanisms for pituitary tumorigenesis investigated in this 
thesis are linked to AIP protein, for which there is a clear evidence of an involvement 
in the pathogenesis of pituitary adenomas.  
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1.4.1 AHR  
AHR is a member of the basic helix-loop-helix/ Per-ARNT-Sim (bHLH/PAS) family 
of transcription factors, formerly discovered as cytosolic receptor for the persistent 
environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD, 
also commonly referred to as TCDD or dioxin)104,105. AHR was found after its 
activation ligand-mediated to up-regulate cytochrome P450 (CYP) CYP1A1 and 
CYP1A2 and other gene products, mainly involved in xenobiotic metabolism106. 
Later on, a wide variety of structurally different compounds was found to bind AHR, 
including other aromatic environmental pollutants, pharmaceuticals, and 
compounds of natural origin synthetized by microbes, plants or endogenously within 
the human body107. However, in addition to TCDD, the majority of high-affinity AHR 
agonists are synthetic chemicals, including polychlorinated biphenyls (PCBs) 
dibenzo-p-furans (PCDF) and dibenzo-p-dioxins (PCDD), benzo[a]pyrene (BαP), 3-
methylcholanthrene (3MC) and β-naphtoflavone (βNF)107,108.  
1.4.1.1 AHR signaling 
AHR possesses both nuclear localization (NLS) and nuclear export sequences 
(NES), therefore is continuously shuttled between the nucleus and the cytoplasm. 
In absence of ligand AHR is inactive, confined in the cytoplasm and associated in a 
complex formed by two heat shock protein 90 (HSP90), p23 and AIP molecules. 
AHR is also reported to interact in its inactive form with other cytosolic proteins 
including the chaperone Cdc37 and the non-receptor tyrosine kinase Src, exerting 
a crosstalk with the MAPK signaling cascade109,110 (Figure 1.4). The HSP90 
molecules have the function to mask the ligand-binding site and the NLS in the AHR 
molecule111, whereas AIP interacts with AHR and HSP90 in order to stabilize the 
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complex112. Moreover, AIP seems to protect AHR against ubiquitination and 
proteosomal degradation113. The co-chaperone p23 plays a role in ligand 
responsiveness and the process of AHR activation114.  
Ligand-binding induces morphological alterations in the structure of AHR allowing it 
to switch into its active form and dislocate from the stabilization complex. Exposure 
of the NLS leads to the translocation of AHR in the nucleus, where it dimerizes with 
its partner AHR nuclear translocator (ARNT), also known as hypoxia inducing factor 
β (HIF-1β). The formed heterodimer is transcriptionally active and binds to 
xenobiotic responsive elements (XREs), which contain the core bases 5´GCGTC-3´ 
in promoter enhancer regions of target genes. Large scale analyses have been 
conducted in order to understand the genes influenced by AHR activation, but the 
results obtained were differently variable in relation to different cellular models 
tested and the dependence on the chemical properties of the AHR ligands used. 
Despite the variability observed, results showed little overlap for a subset of target 
genes named after “The AHR battery”. These genes include CYP1A1, CYP1A2, 
CYP1B1, AHRR (AHR repressor), NQO1 (NAD(P)H quinone oxidoreductase 1), 
ALDH3A1 (aldehyde dehydrogenase 3 family, member a1), UGT1A6 (UDP 
glucuronosyltransferase 1 family, polypeptide A6), and GST-Ya (glutathione S-
transferase)115. 
In addition to the well-known effects of AHR activation in response to the ligand 
TCDD (wasting syndrome, teratogenicity, hepatotoxicity, neurotoxicity, 
immunotoxicity, and oncogenesis), several studies have elucidated the effects of 
AHR activation at the molecular level. For example, constitutive overexpression of 
AHR in transgenic mice reduced the life span of the mice and induced tumors in 
liver and in the glandular part of the stomach116,117, suggesting the necessity for the 
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cell to regulate AHR levels by avoiding its excessive activation or expression in order 
to maintain cellular health. In fact, feedback mechanisms for regulating AHR 
activation were discovered at different steps of the molecular signaling cascade 
(Figure 1.4): 
a) Xenobiotic metabolizing enzymes oxidize polycyclic aromatic hydrocarbons, 
facilitating their removal by ATP dependent membrane transporters115;  
b) The cellular pool of AHR is reduced by proteasome degradation118; 
c) The activity of AHR is modulated by NES present in AHR119; 
d) AHR activation induces the expression of AHRR due to the presence in AHRR 
promoter of XRE sequences (see paragraph 1.4.2.4 and 1.4.2.5)120. 
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Figure 1.4: Schematic pathway representing AHR activation and regulation. In absence of 
ligand, AHR is mainly located in the cytoplasm, forming a complex with AIP, p23, HSP90, Cdc37 and 
Src. The binding of the ligand induces a conformational change in AHR switching it to its active state, 
resulting in nuclear translocation and release of the associated proteins. Activated AHR dimerizes 
then in the nucleus with ARNT and the neo-formed heterodimer induces the transcription of target 
genes including CYP1A1 and CYP1A2 involved in xenobiotics metabolism and AHRR. Different 
mechanisms act for regulating AHR activity or expression: a) xenobiotic metabolizing enzymes 
mediate ligand degradation; (b) AHR is degraded in the proteasome; (c) AHR is exported in the 
cytoplasm due to NES; (d) AHR/ARNT induces the expression of AHRR. Adapted from Hao et al., 
2013115. 
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1.4.1.2 The tumorigenic role of AHR activation 
Apart from the role of AHR in mediating the effects of exogenous ligands, its 
endogenous expression has been correlated with many biological processes 
including development, immunity and cancer biology121–123. A recent study from a 
panel of 967 different cell lines from the Cancer Cell Line Encyclopedia reported 
that AHR is expressed among a wide variety of cell lines including those from breast, 
liver, lung, prostate, stomach and colorectal cancers. Skin-derived cell lines and liver 
cancer cell lines express relatively high levels, whereas many subtypes of leukemia 
cells express low AHR mRNA levels124. Genetic and mutagenesis studies in vitro in 
cancer liver cell lines proved that AHR expression and activity have tumor-promoting 
effects, influencing growth potential and cell-cycle dysregulation125. In contrast to 
these findings, experiments conducted by inducing liver adenomas in transgenic 
AHR−/− mice suggested a tumor-suppressor like activity of AHR126. The role of AHR 
has also been investigated in cell lines derived from other types of tumors, exhibiting 
both oncogenic and tumor-suppressive properties in a cell context-dependent way. 
AHR knockdown in H508 colon cancer cells did not affect cell growth; conversely, 
in vivo studies in transgenic AHR−/− mice showed that the loss of AHR resulted in 
the spontaneous formation of colonic polyps and cecal tumors127. Variable results 
were also obtained in breast cancer derived cell lines: AHR silencing in MCF-7 and 
BT474 cell lines and the BαP resistant cell line T47D (expressing low levels of AHR) 
showed increased cell proliferation, whether slow growth was reported in BαP 
resistant MCF-7 cells128,129. Immortalized mammary tumor fibroblasts derived from 
AHR+/+ and AHR−/− mice were used as models for showing that AHR is required 
for tumor growth in a subcutaneous mouse xenograft model and AHR loss was 
associated with decreased migration and angiogenesis130. Constitutive expression 
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of AHR in transgenic mouse models led to the development of stomach lesions, 
stomach cancer and liver cancer116,117, whereas constitutive AHR overexpression in 
MCF-7 cells and Jurkat T cells inhibited growth in both cell lines and also induced 
apoptosis in Jurkat cells131,132. These reports seem contradictory but they could just 
reflect differences in the impact of AHR activation that are cell-context dependent or 
could differ between adenomas and carcinomas. A novel description of the 
consequences of AHR activation and its relation to tumorigenesis could be found in 
cellular senescence. In fact, cellular senescence plays an important role in 
carcinogenesis as demonstrated in RAS-induced tumorigenesis model of 
premalignant and malignant lung adenomas, suggesting the role of senescence is 
a barrier that tumors have to overcome in order to reach their malignant form73. In 
the study by Ray et al. 2003, primary human keratinocytes were cultured in 
presence or absence of the AHR ligand TCDD. The activation of AHR increased the 
differentiation of the cell line and led to the inhibition of SA-β Gal staining in the 
differentiating keratinocytes accompanied by decreases in cell cycle regulatory 
proteins p53, p16INK4a and p14ARF, supporting the idea that the activation of AHR 
by TCDD is a tumor-promoting event through the inhibition telomere-independent 
senescence response133. These findings may be restricted to this peculiar cellular 
context; therefore, further studies need to be performed in order to clarify the 
hypothesis of senescence as a barrier for preventing malignant transformation134.  
1.4.1.3 AHR and the pituitary gland 
The effect of chemical pollutants has been extensively studied in the endocrine 
system, due to the finding that dioxin-like chemicals could interfere with the 
endocrine system by affecting development and reproduction. For this reason 
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pollutants which have been discovered to work as agonist or antagonists to natural 
hormones have been generally named after endocrine disruptors (EDs). AHR is 
widely expressed in endocrine tissues and its activation by dioxin-like ligands has 
been shown to modulate pituitary function. The first evidence of the effect of AHR 
activation in the pituitary has been reported by Elango et al., 2006. In this study, 
exposure of rainbow trout pituitary cells to TCDD induced both GH and PRL mRNA 
expression partly through the modulation of the activity of AHR135. An in vitro study 
by Moran et al., 2012 investigated the role of AHR activation in pituitary cells with a 
different AHR ligand. GH3 cells in which AHR was activated by treatment with β-
naphtoflavone showed a suppression of AHR expression and an impairment of the 
expression of PRL without affecting the expression of GH mRNA136. More recently, 
treatment of primary cultures obtained from mouse pituitary glands with dioxin-like 
PCBs displayed no effect in modulating apoptosis137. Taking into account the long-
term presence of TCDD in the human body, Landi et al., 2003 investigated the 
incidence of pituitary tumors in the population exposed to the pollutant following the 
industrial accident in Seveso area in 1976138. Despite the impressive availability of 
epidemiological and clinical data, no increase of the incidence of pituitary adenoma 
was registered in the involved area139. In one study evaluating the expression of 
AHR in normal pituitaries and in a subset of human pituitary adenomas, a 
contemporary reduction in AIP and AHR expression was detected in the most 
invasive tumors independently from the presence of AIP mutations, suggesting a 
possible correlation between AHR and tumor aggressiveness140. Additional findings 
confirmed the latter hypothesis. The AHR gene rs2066853 polymorphism was found 
to be more frequent in acromegalic patients than in healthy patients, and was also 
associated with increased disease aggressiveness141. More recently, genetic 
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variants potentially affecting AHR pathway were found to be associated with a more 
severe acromegaly, increased pituitary tumor size, and somatostatin analog 
resistance in patients living in highly polluted areas142. 
1.4.2 AHRR 
AHRR is a member of the bHLH/Per-ARNT-Sim protein family and has been found 
to act as a repressor of the AHR function143. It has been formerly isolated by Mimura 
et al., 1999 during the screening of a mice genomic library using AHR as 
hybridization probe. The newly discovered polypeptide was able to repress the 
transcription activity of AHR by competing with AHR in forming a heterodimer with 
ARNT and binding to XREs, also called AHR responsive elements (AHREs). The 
expression of AHRR was induced by the AHR/ARNT heterodimer through binding 
to the enhancer sequence XRE upstream of the AHRR gene, establishing a 
feedback negative mechanism for the regulation of AHR activity120. However, further 
studies determined that the mechanism of AHR repression seemed to be more 
complex than the one reported herein (see paragraph 1.4.2.5). AHRR shares high 
amino acid (aa) identity with AHR for ~275aa in the N-terminal part of the protein 
that contains the bHLH and Per-ARNT-SIM domains, but the two proteins are highly 
divergent thereafter144. Consistent with the lack of the PAS-B domain that in AHR is 
responsible for ligand-binding, AHRR is reported to act in a ligand-independent 
manner120.  
AHRR is constitutively expressed at mRNA levels in many adult tissues, especially 
in testis, lung, spleen, heart and kidney. In some tissues that express high mRNA 
AHR levels, such as in the liver, basal AHRR expression is low and in some cases 
it was just detectable after the induction of AHR activity with its ligands, thus 
confirming the interdependence between AHRR and AHR143,145–148. However, it is 
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important to consider that mRNA expression levels did not always correlate with the 
expression at protein level. Hence, further data is needed in order to understand the 
more about the regulation of AHRR expression144. In addition to the presence of the 
XRE enhancer sequence, several other regulatory elements were identified in the 
upstream region of the AHRR gene. These include GC box sequences that are 
responsible for AHR-ligand induced AHRR transcription in murine or human 
models149, and an NF-kB binding site which promotes AHRR transcription after the 
stimulation with an NF-kB activator120. These regulatory elements are also 
supposed to regulate AHR levels in basal conditions144.  
Finally, AHRR was also suggested to play a role in development, following the 
finding of its high expression in fish and amphibian embryos and in mammalian 
fetuses compared to adult tissues144,150–154. Some studies had contradictory results 
in supporting this theory: in fact, knockdown of one of the two AHRR paralogs that 
have been found in zebrafish caused developmental abnormalities, whereas 
transgenic mice lacking AHRR did not show abnormal development155,156, 
underlining that further investigations are needed in order to clarify this putative role 
of AHRR.  
1.4.2.1 Hypotheses for AHR repression 
There is no doubt that the primary role of AHRR is repressing the activity of AHR. 
Several studies have extensively demonstrated this function, mainly through 
investigating the expression of the genes prominently implicated in the AHR 
pathway (AHR itself, CYP1A1) in relation to the basal levels of AHRR in different 
tissues or after the modulation of the expression of one of these genes in different 
cell lines. However, the molecular mechanisms driven by AHRR have not been 
 42  
 
completely explained. It is clear by now that AHRR is ligand-independent (due to 
the absence of the PAS-B domain, which is part of the ligand binding pocket is 
AHR)144 and constitutively localized in the nucleus (the NLS of AHRR is dominant 
over its NES)157, but the molecular mechanism by which AHRR represses the 
transcription of AHR is still uncertain. The authors of the initial studies in which 
AHRR was defined as the repressor of AHR proposed two mechanisms of 
repression: the competition between AHR and AHRR for binding with ARNT and the 
competition of the heterodimers AHR/ARNT and AHR/AHRR for binding to the DNA. 
The demonstration of the effective binding of AHRR to ARNT and the binding of the 
complex to AHREs made both of these hypothesis seem plausible120. A further 
analysis ended up with a more complex molecular mechanism explaining the 
interactions between AHR, AHRR and ARNT. The overexpression of ARNT showed 
no effect in the AHRR-mediated repression of AHR, demonstrating that the 
competition between AHR and AHRR for ARNT is not the primary mechanism that 
occurs in AHR repression. In addition, a mutant defective in AHRE binding but with 
an intact NLS was constructed to test the competition for binding to AHRE, 
demonstrating that even the binding to AHRE did not seem to be necessary for AHR 
repression, although a slight decrease in repressive potency of the mutant was 
reported. These results suggested an additional mechanism to the ones initially 
reported that might involve transrepression through protein-protein interactions, 
independent from binding to AHREs, but still the specific interactions involved need 
to be verified144,146 (Figure 1.5). 
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Figure 1.5: Mechanism of repression of AHR by AHRR. AHRR competes with AHR for 
dimerization with ARNT; moreover, AHRR/ARNT competes with AHR/ARNT for binding with AHREs, 
as proposed by Mimura et al., 1999120. A second putative mechanism may involve transrepression, 
independently for competition with ARNT or AHREs, and it is these protein-protein interactions are 
ARNT-mediated or not. Adapted from Hahn et al., 2009144. 
1.4.2.2 AHRR and the pituitary gland 
Due to the intensive investigation of dioxin-like pollutants as EDs, several studies 
have analyzed the impact of AHR activity in the epidemiology of pituitary tumors, 
but little is known about the role of AHRR. Two different studies investigated the 
response of AHR-responsive genes using in vitro and in vivo models, and both of 
them confirmed the presence of a functional response to the induction of AHR 
activity by some of its ligands in the pituitary. In the first study, an increase in the 
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mRNA levels of AHRR was reported after the treatment of AtT-20 cells with TCDD 
and β-NF, whereas only TCDD treatment was shown to induce AHRR mRNA 
expression in vivo in mice158. In the second study, the response to TCDD exposure 
was investigated in vivo with the main aim to identify a possible connection between 
toxic damage by TCDD and vitamin A homeostasis. Despite the higher basal levels 
of AHRR in the pituitary of the knockout mice in comparison to the control strain, no 
difference was found in AHRR expression after AHR activation between knockout 
and wildtype mice159.  
1.4.2.3 AHRR and cancer 
Several studies reported the involvement of AHR in the development of different 
types of tumors116,117,123, but still little is known about the tumorigenic potential of 
AHRR. Kanno et al., 2006 demonstrated that AHRR overexpression in the human 
breast cancer cell line MCF-7 led to decreased cell proliferation and to decreased 
expression of cell-cycle related and estrogen-responsive genes160,161. In addition, 
AHRR was found to be downregulated by hypermethylation in human malignant 
tissues from different anatomical origins including colon, breast, lung, stomach, 
cervix and ovary162. In particular, levels of promoter hypermethylation were closely 
correlated with cancer grade in cervical and esophageal cancer. These data suggest 
that in those tissues AHRR might act as a tumor suppressor gene. Furthermore, 
AHRR in vitro silencing in MCF-7 and A549 cell lines increased cellular growth and 
clonogenic potential in addition to motility, resistance to apoptosis and angiogenic 
ability162. At present AHRR expression in the pituitary has been investigated only in 
few studies147,158,159,163. These studies underline the importance of further research 
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activity focusing on understanding the relevance of AHRR activity in tumorigenesis 
beyond the already known activity of AHR repression. 
1.4.3 HSP90 
HSP90 is an evolutionarily conserved and ubiquitous molecular chaperone required 
for correct folding and maturation of a variety of cellular proteins, accounting for 1-2 
% of total cellular protein levels even under basal conditions164,165. It has been 
detected in almost every compartment of eukaryotic cells, including cytosol, 
nucleoplasm, endoplasmic reticulum and mitochondria. In the eukaryotic cell, 
HSP90 exerts essential housekeeping functions by stabilizing or activating a vast 
array of proteins, generally termed as ‘clients’, which comprehend more than 200 
proteins by now (for an up-to-date list refer to https://www.picard.ch/downloads). 
These encompass kinases, transcription factors and an array of signaling molecules 
involved in a wide range of biological processes165–167. HSP90 can also promote 
protein degradation through a passive activity leaving clients unfolded after many 
rounds of chaperone binding and release, after which the protein is more likely to 
encounter the ubiquitin ligases that would mark it to proteasome degradation, as 
reported for Von Hippel–Lindau disease tumor suppressor (VHL)168. HSP90 does 
not just exert its role in basal conditions, but especially in adaptive response to 
different sources of cellular stress (including heat, heavy metals, hypoxia and 
acidosis), in which its expression approximately doubles164. Inducible transcription 
of HSP90 is controlled by the transcription factor Heat Shock Factor 1 (HSF1), which 
induces several genes in response to environmental stress169. HSP90 plays also a 
role in cancer, due to the fact that cancer cells use the chaperone activity of HSP90 
and its related proteins to protect mutated or overexpressed oncoproteins from 
misfolding and degradation170. Although in general relatively abundant, HSP90 does 
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not function alone, but as a component of a larger molecular complex that includes 
other chaperones such as HSP70, co-chaperones, modulators of its activity and 
diverse accessory proteins.  
HSP90 is a member of the GHKL superfamily (that also comprises DNA gyrase, 
histidine kinase and the DNA mismatch repair protein MutL)171. The protein is 
composed of a homodimer, and each monomer has a highly-conserved amino-
terminal domain (NTD) connected to a middle domain, followed by a carboxy-
terminal domain (CTD). NTD has a α/β sandwich structure in which the helices form 
a pocket. HSP90 binds ATP in NTD, hydrolyzing it and following the interaction with 
clients, and the stabilizing interaction between the two monomers seems to enhance 
this activity164,171,172; this function was demonstrated as necessary for the biological 
function of HSP90173,174. A middle segment connects the NTD and the CTD and has 
a role in ATP hydrolysis due to the presence of a key-catalytic residue171. The CTD 
of HSP90 is a dimer of a small mixed α/β domain that mediates the dimerization of 
the homodimer and is less conserved in sequence than the rest of the protein. 
Although a low-affinity nucleotide-binding site has not been confirmed, the five C-
terminal residues forming the Met-Glu-Glu-Val-Asp (MEEVD) motif make up a highly 
conserved TPR domain-binding site, which mediates interaction with many co-
chaperones175. This binding site has a particularly important role, which is to 
facilitate the cooperative action of HSP40, HSP70 and HSP90 on client proteins to 
achieve client maturation164. 
1.4.3.1 HSP90 chaperone complex and cancer 
HSP90 is involved in the maturation and stabilization of a wide variety of oncogenic 
proteins (Bcr-Abl, HER-2, EGFR, C-Raf, B-Raf, Akt, Met, VEGFR, FLT3, AR and 
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ER, HIF-1α)176, which has stimulated the investigation of its possible role in tumor 
progression. Increased expression of HSP90 or other HSPs has been mainly 
reported in human cancers, solid tumors and hematological malignancies170. 
Recently, overexpression of HSP90 has also been reported in corticotroph 
adenomas177. The first evidence of HSP90 altered expression in cancer was 
reported in one study in which HSP90 overexpression was found in humane acute 
leukemia cells and was correlated with increased proliferation178. Later on, 
overexpression of HSP90 and HSP70 was reported in breast cancer and associated 
with bad prognosis, suggesting that HSP90 might act at different level in tumor 
development179. An increased overexpression of HSP90 might reflect at 
physiological level the possibility for the tumor cell to survive in a condition of stress, 
and at molecular level to permit to the oncogenic client to exert its tumorigenic effect. 
Increased survival might be also linked to a resistance to apoptotic stimuli170. For 
instance, some co-chaperones of HSP90 modulate tumor cell apoptosis, having 
mainly effects on Akt180, tumor-necrosis factor (TNF)-receptors181 and NF-κB 
function182. Oncogenic mutations of clients may probably lead to higher 
requirements for HSP90 function, probably due to an increased conformational 
instability of the mutated protein. One example of this phenomenon is provided by 
the tumor suppressor protein p53, which is encoded by the gene TP53. Several 
mutations in this gene lead to the protein with altered conformation and activity of 
the protein. Wildtype p53 interacts with HSP90 and is quickly marked to proteasome 
degradation183,184; conversely, altered p53 proteins are longer retained by HSP90 
and accumulate in the cell exerting their tumorigenic role. These data suggest that 
cancer progression can be highly dependent on HSP90 and its client activity. 
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Therefore HSP90 is being investigated as a potential target for cancer 
therapeutics185. 
1.4.3.2 HSP90 inhibitors 
There are many reasons why HSP90 should be considered as a target for cancer 
therapy. First of all, as cited in the previous paragraph, HSP90 acts as a chaperone 
for diverse proteins which play a role in carcinogenesis. Secondly, as a 
consequence of the need for stabilization of mutated oncoproteins, HSP90 shows 
to have a higher affinity for ATP binding, which could favor the binding of inhibitors 
that interact in this region of the protein. Thirdly, HSP90 is more expressed in tumor 
cells when compared to non-tumorigenic cells, suggesting a vital role of this protein 
in tumor cell survival176,186. Several HSP90 inhibitors have been discovered and 
designed so far, and can be generally divided based on their site of action, that is 
a) N-terminal and b) C-terminal domain of the protein.  
a) N-terminal inhibitors 
The research on HSP90 inhibitors started with the finding that ansamycin antibiotics 
bind the conserved nucleotide-binding pocket of HSP90, blocking the natural 
substrate for ATP binding187. Structural and biochemical studies demonstrated that 
geldanamycin (GA) specifically inhibits only HSP90 by restraining it in its ADP-
bound conformation and prevents the subsequent “clamping” of HSP90 around a 
client protein188,189. In spite of the specificity of the compound, research for more 
efficient derivatives was indicated due to the high hepatotoxicity observed in animal 
studies190. The testing of 17-AAG showed an impressive downregulation of multiple 
HSP90 protein clients and other downstream effectors, such as IGF-IR, Akt, iKK-α, 
iKK-β, FOXO1, Erk1/2 and c-Met, resulting in inactivation of NF-κB, reduced cell 
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proliferation and decline of cell motility191. 17-AAG entered phase I trials and signs 
of therapeutic activity have been found in melanoma, breast cancer, prostate 
cancer, and multiple myeloma192–195, while the few phase II studies performed did 
not show complete or partial response196,197. One important issue about 17-AAG is 
that it leads to the activation of a heat shock response with the activation of the 
transcription factor HSF-1198–200. Another ansamycin derivative, 17-
(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), showed 
downregulation of B-Raf, decreased cell proliferation, reduced Mek/Erk signaling 
activation and induced the inhibition of telomerase activity in melanoma cells201,202. 
Seven clinical trials with 17-DMAG (5 phase I, 2 phase II) have been reported in 
clinicaltrials.gov database until now176,203–205. In addition to 17-AAG and 17-MAG, 
several different derivatives of GA and others distinct from GA have also entered 
clinical trials and are currently in the preclinical stage of development176. Another 
important inhibitor of the N-terminal domain of HSP90 is radicicol, a macrocyclic 
natural antibiotic initially isolated from the fungus Monocillium nordinii and 
Monosporium bonorden206,207. Radicicol activity in inhibiting HSP90 is comparable 
to that of ansamycin derivatives208. Despite from its antitumoral activity in vitro, the 
compound showed little or no activity in vivo, due to its chemical and metabolic 
instability209,210.  
b) C-terminal inhibitors 
Generally unsatisfactory results with N-terminal inhibitors in experimental trials 
resulting from increased toxicity and stress response led to the focus on the C-
terminal region of HSP90 for the development of novel and improved inhibitors. 
Novobiocin, a coumarin antibiotic isolated from Streptomyces species211, and its 
analogues clorobiocin and coumerymicin A1 were found to bind strongly to DNA 
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topoisomerase II but weakly to the HSP90 C-terminal binding site, inducing the 
degradation of client proteins such as v-Src, Raf-1, Erb2 and mutant p53212,213. 
Moreover, novobiocin was also able to disrupt the interaction of the co-chaperones 
p23 and HSP70 with the HSP90 complex214. Despite initially promising results, 
novobiocin showed low efficacy against cancer cells in further trials, leading to its 
disqualification as an HSP90 inhibitor in medical applications215. Structural 
modifications of this compound led to the conception of analogues with 1,000-fold 
greater efficacy in antiproliferative assays against various cancer cell lines176. For 
instance, the novobiocin-derived HSP90 inhibitor KU135 induced antiproliferative 
effects in Jurkat cells which were higher than the ones produced by 17-AAG, and 
caused the degradation of HSP90 client proteins. The compound was as potent 
inducer of the intrinsic apoptosis, and did not induce upregulation of HSP90 and 
HSP70 as 17-AAG did. Moreover, KU135 showed a G2/M arrest, whereas cells 
treated with 17-AAG accumulated in G1 phase in the cellular model used. These 
results suggest that KU135 is effective by potentially regulating signaling pathways 
different from those affected by 17-AAG treatment216. A further investigation of the 
effects of KU135 in melanoma cells, in addition to confirming some of the findings 
of the previous study, reported that KU135 induced apoptosis and reduced HSP90 
client proteins BRAF, Raf-1, cyclin B and cdc25217. Tests on the more recent C-
terminal inhibitor KU174 in prostate cancer cells exhibited robust antiproliferative 
and cytotoxic activity together with client proteins degradation and disruption of 
HSP90 native complexes without inducing a heat shock response in cells. In 
addition, in a pilot in vivo study in a rat xenograft tumor model displayed that KU174 
was effective in reducing tumor volume without signs of apparent toxicity, although 
the presence of vehicle toxicity was reported, especially in the kidney218. Silibinin, 
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the major bioactive constituent present in the flavonoid extract of milk thistle 
silymarin, has been widely used as a hepatoprotective agent as well as a nutritional 
supplement to protect the liver from diseases associated with alcohol consumption 
and exposure to chemical and environmental toxins219. Recent studies have 
demonstrated that silibinin exerts cytotoxic activity against cancer cell lines, in this 
case by exhibiting HSP90 inhibitory activity220. The compound displayed effects on 
cell viability, induced G1 cell cycle arrest, inhibited EGFR and NF-κB, down-
regulated survivin and suppressed angiogenesis220,221. 
Due to the finding of HSP90 overexpression in a series of corticotroph adenomas in 
comparison to normal pituitary, and considering the known interaction between the 
glucocorticoid (GR) receptor with HSP90222, the effect of N-and C-terminal HSP90 
inhibitors has also been evaluated in this type of pituitary tumors. In this case, 
silibinin caused the release of mature GR from HSP90, increasing the number of 
stable GR receptors and partially restoring glucocorticoid sensitivity177. This 
discovery offers a novel therapeutic approach for the management of corticotroph 
adenomas, opening the door to HSP90 inhibitors as alternative agents in pituitary 
tumor treatment. 
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2. Aims of the study 
The overall aim of the present study was to investigate novel molecular mechanisms 
involved in pituitary adenomas development, especially in the context of the GH-
secreting ones.  
The main objectives were: 
1) To evaluate the impact of the modulation of AHRR in the development of pituitary 
adenomas. This study was performed through the establishment of stable 
transfectants from the somato-lactotroph cell line GH3 for AHRR silencing or 
overexpression; in addition, the expression of AHRR was evaluated in the pituitary 
in a cohort of patients with acromegaly and NFPAs and results were correlated with 
radiological and pathological parameters of pituitary tumor aggressiveness; 
2) To investigate the role of HSP90 in the pathogenesis of GH-secreting adenomas 
and its possible consideration as a novel therapeutical target by testing different 
types of inhibitors of the activity of the protein. 
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3. Materials and methods 
3.1 Pituitary adenoma patients (Study I) 
Diagnosis and management of pituitary disease was done by physicians referring 
to international criteria223,224. Diagnosis of a GH-secreting adenoma was 
estabilished by typical clynical symptoms in conjunction with non-suppression of GH 
levels after standard OGTT administration, IGF-1 values higher than age-gender 
match, and RMN evidency of pituitary adenoma225. Prolactinoma has been 
diagnosed after manifestation of hypogonadism, high-molecular-weight prolactin-
rhythm evaluation and RMN evidency of pituitary adenoma226. For the diagnosis of 
NS pituitary adenomas the absence of clinical and biochemical effects of the tumor 
is necessary67. 
3.1.1 Sporadic patients (Study I) 
The selected cohort consisted of 51 patients that did not report cases of other 
pituitary adenomas in their families. 35 of these were GH-secreting-, 5 GH-and PRL-
secreting and 11 were NS adenomas. Patients were recruited until April 2015 in the 
Endocrinology Division of Padua Hospital/University and operated at the 
Neurosurgery Unit of University/ Hospital of Padua. Tumor phenotype was 
confirmed through immunohistochemical characterization of hormone secretion and 
tumor aggressiveness was classified through radiological and histological criteria227. 
Pituitary tumor samples were maintained in RNA later stabilization solution (Thermo 
Scientific, Waltham, MA, USA) overnight at 4°C and subsequently stored at -20°C 
till the moment of RNA extraction. 
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3.2 Cell culture and treatments (Studies I, II) 
The rat somato-lactortroph pituitary tumor cell line GH3 (American Type Culture 
Collection, Manassas, VA) has been used as a model in study I for evaluating the 
impact of the modulation of AHRR expression and in study II for testing the efficacy 
of HSP90 inhibitors. Cells were seeded in DMEM 10% prepared as follows: DMEM 
low glucose medium (Euroclone, Pero, Italy) supplemented with 10% FBS, 2mM L-
Glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco, Carlsbad, CA, 
USA) and the cells were propagated in a fully humidified atmosphere of 5% 
CO2/95% air at 37°C.  
For GH3 treatment in the study II the following compounds have been tested: 17-
AAG (Tocris Bioscience Bristol, UK), novobiocin (Sigma-Aldrich, MI, USA) and 
KU174 (University of Kansas, KS, US.). All the tested substances were dissolved in 
DMSO. Cell treatments were performed 24 h after cell seeding by diluting the 
compounds or vehicle in DMEM 2% (DMEM low glucose supplemented with 2% 
FBS, 2mM L-Glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.  
3.3 Establishment of stable cell lines (Study I) 
The stable expression of a gene of interest consists in its permanent expression in 
the cell line used. At first, the gene of interest has to be introduced into the cell, then 
subsequently into the nucleus, and finally has to be integrated into the chromosomal 
DNA (Fig. 3.1). The event of integration in the total population of cells transfected is 
rare and the only way to maintain the population stable is a sustained selection 
against those cells that have lost the plasmid. For the selection of stably-transfected 
cells, a selection marker is co-expressed on either the same construct or on a 
second, co-transfected vector. There is a variety of systems for selecting transfected 
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cells, including resistance to antibiotics such as neomycin phosphotransferase, 
conferring resistance to G418, dihydrofolate reductase (DHFR), or glutamine 
synthetase228. After transfection, cells are kept in medium containing the selective 
agent, and only those cells containing the drug-resistant gene who will have 
permanently integrated the plasmid will survive. 
 
Fig. 3.1: General procedure for generating stable cell lines. The plasmid containing the gene of 
interest and the gene for drug selection are introduced in the cell through transfection (A). 
Subsequently, through prolonged drug selection the plasmid is integrated in the nucleus (B) and 
finally in the chromosomal DNA (C). Taken from http://bio.lonza.com 
There are different choices for generating stable cell lines, depending on time and 
aim of the study. A mixed population for drug resistant cells can be used for 
experiments, having the possibility to obtain results in a relatively low amount of 
time, with the disadvantage of having a genetically mixed population because the 
plasmid will be integrated in random parts of the host chromosomal DNA. Another 
possible approach consists in diluting transfected cells on a large scale, so that each 
culture will theoretically be derived from a single clonal cell. An important 
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disadvantage of this technique is the amount of cell passages needed to reach a 
suitable amount of cells for testing and creating a storage, negatively influencing the 
reproducibility of the results due to an increased probability of cell differentiation. 
The generation of stable cell lines is useful for a wide range of applications, such as 
gene function studies, drug discovery assays, or the production of recombinant 
proteins.  
In this work, stable cell lines were generated from the cell line GH3 for 
overexpressing or silencing of AHRR, establishing mixed populations as described 
in Figure 3.2. Twenty-four hours before the transfection, 7X104 cells/well were 
seeded in 24-well plates. Transfection was performed using 1 μl of Lipofectamine 
2000 (Invitrogen, Milan, Italy) and 0.8 μg of plasmid DNA. Plasmids carrying shRNA 
sequences for AHRR silencing, overexpression and respective controls were 
generated by SABiosciences-Qiagen (Venio, Netherlands) (see appendix 1). To 
obtain stable cell lines, selection pressure was maintained by supplementing culture 
medium with puromycin (1µg/ml, Gibco) for a period of two weeks. After this period, 
puromycin concentration was scaled down to 0,5 µg/ml and kept throughout the 
experimental period. Aliquots of cells have been frozen and kept in -80°C in order 
to prevent high number of passages and restored when necessary. 
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Figure 3.2: General approach for establishing mixed population of stable clones. Cells are 
seeded and transfected with the plasmid containing the gene of interest and the gene for the drug 
resistance. After the transfection, the selection medium is added and surviving cells are the ones 
who integrated the plasmid. Subsequently recombinant cells are expanded and tested for the 
expression of the gene of interest and the relative protein of interest (Modified from 
http://www.creative-biogene.com).  
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3.4 RNA Extraction (Study I) 
Total RNA was extracted from GH3 cells to confirm at mRNA level the effective 
silencing or overexpression of AHRR and from pituitary tissues for evaluating AHRR 
mRNA expression in the cohort. Rat pituitary cells and human pituitary adenoma 
samples were lysed and homogenized in TRIzol (Invitrogen) and processed 
according to manufacturer´s instructions. Briefly, chloroform (Carlo Erba, Val de 
Reuil, France) was added to the sample to separate RNA from proteins and DNA 
from RNA. The phase containing the RNA was collected and precipitated by adding 
isopropanol (Carlo Erba), and contaminants were washed away. The pellet 
containing RNA was then resuspended and washed with ethanol 75% (Carlo Erba) 
and when dried was furtherly resuspended in RNAse free water. 
3.5 Determination of RNA concentration and purity (Study I) 
The yield of purified RNA was then determined by a Nanodrop spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA). Using fiber optic technology and 
surface tension, this technique permits a high accuracy in determination of nucleic 
acids quality and concentration in microvolumes of samples. The concentration of 
the nucleic acids is automatically calculated by the NanoDrop software through the 
formula: A260 X 44 μg/ml X dilution factor. Purity of the DNA or RNA is determined 
by the ratio A260/A280. For RNA, a ratio between 1.8-2.0 indicates little or no protein 
contamination. 
3.6 DNAse treatment and determination of RNA integrity (Study I) 
Total RNA was incubated with DNAse I (RNAse free) endonuclease (Thermo 
Scientific) according to the manufacturer´s instructions, in order to remove genomic 
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DNA contaminations that could have derived from a non-excellent phase separation 
of the lysate with chloroform (see paragraph 3.4). To verify the integrity of the 
purified RNA and the quality of the purification, 500ng of the samples were run in a 
denaturing 1% agarose gel stained with Etidium Bromide solution (Sigma-Aldrich). 
The samples showed as expected 28S and 18S bands of ribosomal RNA (rRNA), 
with 28S bands approximately twice intense as the 18S band as good indication of 
RNA integrity. The absence prominent bands above the rRNA ones after the DNAse 
treatment certified the removal of genomic DNA contamination. 
3.7 Reverse Transcription of RNA (Study I) 
Single strand cDNA was obtained in a reaction of reverse transcription by loading 
500 ng of DNAse-treated RNA and using random examers as primers and. and M-
Mulv reverse transcriptase (Euroclone, Pero, Italy), following manufacturer´s 
instructions. 
3.8 Real-time PCR (qRT-PCR) (Study I) 
The technique of Real-time PCR (qPCR) is based on a polymerase chain reaction. 
The cDNA is amplified and the amount of nucleic acid is quantified through 
fluorescent reporter dyes. The increase in fluorescence signal during the reaction is 
proportional to the amount of DNA produced during each PCR cycle. Using probes 
with different reporter dyes allows the detection of multiple target genes in the same 
reaction. The parameter considered for determination of cDNA amplification is the 
quantification cycle (Cq), that is the number of cycles in which fluorescence exceeds 
the threshold. The more target is in the starting material, the lower is the Cq. Gene 
expression was quantified by qPCR with with an ABI PRISM 7900HT Sequence 
Detector (Applied Biosystems, Waltham, MA, USA) based on EXPRESS qPCR 
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Supermix containing a ROX passive reference dye and Taqman gene expression 
assays (Thermo Scientific) with coverage of all human (Hs01005075_m1) or rat 
(Rn01537444_m1) AHRR transcript variants. To compensate relative differences 
between samples the results obtained were corrected in rat pituitary cells for ACTB 
(Rn00667869_m1) and in human pituitaries for HMBS (HS00609296) expression, 
which showed higher stability than other common housekeeping genes in the 
pituitary tissue229. All of the gene expression assays consist of a pair of unlabelled 
PCR primers and probes with different dye labels on the 5´end and a nonfluorescent 
quencher at the 3´end (Figure 3.3). 
 
Figure 3.3: Taqman Probe chemistry mechanism: TaqMan probes consist of a fluorophore 
covalently attached to the 5’-end of the oligonucleotide probe and a quencher at the 3’-end. When 
the fluorophore and the quencher are in proximity, quenching inhibits any fluorescence signals. 
Probes anneal within a region of DNA amplified by two primers. During the PCR reaction, cleavage 
and consequent degradation of the probe by the exonuclease activity of the Taq polymerase releases 
the fluorophore from it, allowing fluorescence of the fluorophore due to deactivation of the quenching 
effect. The fluorescence detected from the thermal cycler is directly proportional to the template 
present in the PCR. Taken from http://www.wikipedia.com. 
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qPCR experiments were performed following the MIQE guidelines230. All samples 
were assayed in triplicates using a MicroAmp 96-Well reaction plate sealed with an 
Optical Adhesive Film (Applied Biosystems) using 50 ng of rat cDNA or 20 ng of 
human cDNA template in a reaction mixture of 20 µl. No template controls were 
included with each run as negative controls. In order to check the efficiency of the 
PCR reaction a standard curve with different dilution of a given cDNA sample has 
been generated231. qPCR conditions were according to the following scheme: 95°C 
for 2 minutes (denaturation), 45 cycles at 95°C for 15 second (annealing/extension), 
60°C for 1 minute (dissociation). Data were analysed with the Sequence Detection 
Software 2.4 (Applied Biosystems) with an automatically-set baseline and a 
fluorescence threshold adjusted for measuring Cq values. Evaluation of gene 
expression results has been performed using the 2-ΔΔCT method231. 
3.9 Protein Extraction and quantification (Study I, II) 
Protein extraction was performed from GH3 cell lysates in study I to confirm the 
stable silencing or overexpression of AHRR at protein level and in study II to 
evaluate the effects of the inhibition of HSP90 activity on HSP90 client proteins. 
After the removal of cell culture medium cell lysis buffer RIPA with proteases 
inhibitors (MgCl2 10mM, Pepstatin 1 µM, PMSF 1 mM, Complete 1X (Roche, 
Monza, Italy)) was added to the cells. Cells were then vigorously scraped from the 
well and the lysates were transferred on 1.5 ml tubes. Samples were clarified by 
centrifugation at 13000 rpm for 5 minutes at 4°C and supernatants were stored at -
80°C. Bradford assay (Biorad, Hercules, CA, USA) was used for protein 
quantification. A set of bovine albumin serum (BSA) dilutions was prepared for the 
standard curve in order to normalise the quantity of proteins loaded for western blot. 
Protein lysates were diluted 1:250 in distilled water and 100 µl were transferred in 
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p96 well plates. 50 µl of a 1:2 solution of Bradford staining diluted in distilled water 
were added to each well. The plate was then inserted on the reader and absorbance 
was read at 595 nm wavelength.  
3.10 Western Blot (Study I, II) 
The Western Blot is a biochemical method that allows a qualitative and semi-
quantitative evaluation of proteins and the effect of different conditions on protein 
levels. It was performed in study I for testing the modulation of the expression of 
AHRR in stable cell lines and in study II for determining the effects of the treatment 
with HSP90 inhibitors on client proteins. 
For each sample, 20 µg were resuspended in NuPAGE SDS sample buffer 
(Invitrogen) and NuPAGE sample reducing agent (Invitrogen), boiled for 10 min at 
70°C and resolved by SDS-PAGE on 4–12% NuPAGE gels (Invitrogen) and MES 
buffer (Invitrogen). Separated proteins were transferred onto nitrocellulose 
membrane by Trans-Blot Turbo transfer system (BioRad). Membrane blocking was 
performed for 2 hours with 5% non-fat dry milk (BioRad). The membrane was 
incubated overnight at 4°C with the primary antibody (a list of the primary antibodies 
used in this thesis is provided in table 3.1). After incubation, the membrane was 
washed 3 times for 5´ with 0.1% Tween 20 (Sigma-Aldrich) in phosphate-buffered 
saline (Sigma-Aldrich) (TPBS) and incubated for 1h at room temperature with the 
relative secondary antibody conjugated with Horseradish Peroxidase (HRP) (a list 
of the secondary antibodies used is provided in table 3.2). Expression was corrected 
for differences in protein loading by probing blots for 1 h at room temperature with 
anti-GAPDH antibody (Study I) or rat anti–ß actin antibody (Study II) and 
subsequently with their relative secondary antibodies as previously described. After 
the incubation with the secondary antibody, the membrane was washed 3 times for 
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5´with TPBS and incubated with chemiluminescent substrate ECL (Thermo 
Scientific) for 1´minute. The detection and density measurements were then 
performed with Chemidoc MP System (Biorad) and Image Analysis Software 
(Biorad). 
 
Antibody Dilution Host Type Manifacturer Study 
Anti-AHRR 1:1000 rabbit polyclonal ABCAM, Cambridge, UK I 
Anti-CREB 1:2000 mouse monoclonal Cell signalling, Danvers, MA, 
USA 
II 
Anti-P CREB 1:1000 rabbit polyclonal Cell signaling II 
Anti-HSF1 1:1000 rabbit polyclonal Novus Biologicals, Littleton, 
CO, USA 
II 
Anti-PIT-1 1:1000 rabbit monoclonal Santa Cruz Biotech, Santa 
Cruz, CA, USA 
II 
Anti-AKT 1:5000 rabbit polyclonal Cell signaling II 
Anti-GAPDH 1:10000 mouse monoclonal Chemicon, Billerica, MA, 
USA 
I 
Anti-β Actin 1:5000 mouse monoclonal Millipore, Billerica, MA, USA II 
Table 3.1: List of primary antibodies used in studies I and II:  
 
Antibody Dilution Host Conjugated Manifacturer Study 
Anti-Rabbit 1:1000-
1:2000 
goat Horseradish 
Peroxidase 
New England Biolabs, 
Ipswich, MA, USA 
I, II 
Anti-Mouse 1:1000-
1:5000 
horse Horseradish 
Peroxidase 
New England Biolabs, 
Ipswich, MA, USA 
I, II 
Table 3.2: List of secondary antibodies used in studies I and II.  
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3.11 Cell viability assay (Study I) 
Cell viability was measured for evaluating the impact of the modulation of the 
expression of AHRR. For this purpose the MTT assay was performed, which is a 
colorimetric assay that detects the conversion of the tetrazolium dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich) to 
formazan, as an indication for active metabolic activity. Briefly, 2.5X103 cells were 
seeded in 96-well plates. Every 24h for 4 days after cell seeding viability was 
measured by adding 5mg/ml of MTT solution to each well. After incubation for 3 h 
at 37°C, the medium was removed and 100 µl of DMSO were added to each well 
and gently mixed to solubilize formazan crystals. Absorbance was measured at 550 
nm with a microplate reader (Victor 3 1420 Multilabel Counter, Perkin Elmer) with 
background subtraction set at 620 nm. 
3.12 Caspase 3-7 assay (Study I) 
The activity of the effector caspase 3/7 was measured in study I to determine the 
possible effect of the modulation of AHRR expression in stable cell lines on the 
induction of apoptotic mechanisms. In this case Caspase-Glo 3/7 assay (Promega, 
Madison, WI, USA) was used, a luminenscent assay that measures caspase 3-7 
activities in cultured cells. Briefly, the assay provides a luminogenic caspase 3/7 
substrate, which contains the tetrapeptide sequence DEVD. The addition of this 
reagent to the cells results in caspase 3/7 cleavage of the substrate and generation 
of a stable luminescent signal, produced by luciferase. Luminescence is proportional 
to the amount of caspase activity present.  
Cells were seeded on 96-weel plates (2.5X104/well) 24 hours before the experiment. 
The following day apoptosis was induced with 8h treatment with the apoptosis 
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inducer Camptothecin (Sigma-Aldrich) at 1µM concentration, using DMSO as 
vehicle. After the treatment early apoptosis was determined by measuring photon 
emission with a microplate reader (Victor 3 1420 Multilabel Counter, Perkin Elmer, 
Monza, Italy) following the addition of the appropriate substrate according to 
manufacturer´s instructions. 
3.13 Flow cytometric analysis of cell cycle (Study I) 
Among its different applications, flow cytometry permits to define different cell types 
in a heterogeneous cell population and analysing cell size and volume. It is mainly 
used for measuring fluorescence intensity produced by fluorescent-labeled 
antibodies detecting proteins, or ligands that bind to specific cell-associated 
molecules. One of the important applications of this technique is the evaluation of 
cell cycle population by using a propidium-iodide staining. The latter, is an nucleic 
acid intercalating agent and a fluorescent molecule that intercalates between the 
bases of DNA in proportion to the amount of DNA present in the cell; in this way, 
different intensities of fluorescent signal will permit to distinguish between cells in 
G1, S or G2 phase.  
Cytofluorimetric analysis was performed in study I for determining eventual 
differences in the distribution of cell cycle population after the stable modulation of 
the expression of AHRR. Briefly, 1,2X105 cells/dish were seeded in 56 mm diameter 
Petri dishes. After 24 and 48h of incubation, cells were rinsed in PBS and 
trypsinized. Trypsin action was then inactivated and the final solution was 
centrifuged at 1200 rpm for 4 minutes. Subsequently, cell pellet was resuspended 
in 10 ml cold PBS. After a second centrifugation at the same time and speed as 
before, the pellet was furtherly dissolved in 1 ml of cold PBS and fixed with 3 ml of 
ethanol 100% kept at -20°C till used. Cells were then maintained for at least 24h at 
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-20°C, until propidium iodide staining. Fixed cells were washed in 1ml cold PBS and 
the pellet was resuspended in 500 µl PBS with 10 µg/ml propidium iodide and 1 
µg/ml RNAse A for 1h at 37°C, followed by analysis in Beckman–Coulter EPICS XL 
(Beckman Coulter, Pasadena, CA). 
3.13 Senescence associated beta galactosidase assay (Study I) 
Senescence-associated beta galactosidase (SA-β Gal) assay is a cytochemical 
assay that detects the senescence-associated activity of beta galactosidase through 
the production of a blue precipitate that results from the cleavage of the 
chromogenic substrate X-Gal98. Potential applications of this assay include 
determining the abilities of different conditions or compounds to induce a 
senescence response or antiaging effects of compounds in culture or in tissue 
samples, or determining the appearance of senescent cells after different types of 
stress. 
Senescence-associated beta galactosidase assay was performed for evaluating the 
possible influence in inducing cell senescence of the stable silencing of the 
expression of AHRR. 3 x 105 GH3 cells were seeded in 6-well plates. After 48h of 
incubation, assuring the absence of a sub-confluent state of growth (confluent cells 
might show aspecific SA-β Gal activity232) cells were washed for 30’’ with 1ml 
PBS/well. Cells were then incubated for 5’ in fixation solution (2% formaldehyde + 
0,2% glutaraldehyde in PBS, 1ml/well). Subsequently, fixation solution was 
removed for adding staining solution, which consists as reported as follows: 
-40mM citric acid/phosphate buffer 
-5mM potassium hexacyanoferrate III 
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-5mM potassium hexacyanoferrate II 
-150mM sodium chloride 
-2mM magnesium chloride 
-1 mg/ml X-Gal 
-distilled water in order to reach the suitable volume. 
Maximal staining was reached after 12-16 h incubation at 37°C in a non CO2 
atmosphere. Subsequently, cells were washed two times for 30’’ with 2ml PBS/well. 
The last solution used for washing was kept and cells were stored in the dark at 4°C. 
Staining was then analysed with an optical microscope and quantification of SA-β 
Gal activity was performed with LAS v1.4 software (Leica Microsystems, Heerbrugg, 
Switzerland).  
3.14 Immunohistochemistry (Study II) 
Immunohistochemistry (IHC) is a powerful method for detecting specific antigens in 
formalin-fixed, paraffin-embedded tissues on antigen-antibody interaction. This 
method was used in study II for detecting HSP90 overexpression in patients with 
GH-secreting tumors. Sections of 8 µm size of frozen tissues were cut in a cryostat 
(Leica CM3050 S, Leica, Wtzlar, Germany) and put on poly-L-lysine coated glass 
slides. The tissue was fixed in freshly prepared cold PBS with 4% paraformaldehyde 
(PFA), dehydrated and stored at 4°C until use. At the moment of the experiment, 
sections were incubated for 5’ in Tris-Buffered Saline solution (TBS) at pH 7.6, 
followed by 30’ blocking in TBS with 10% goat serum. Endogenous peroxidase 
activity was blocked by 15’ incubation with TBS and 1% H2O2. The sections were 
incubated with HSP90 antibody (EPR3953 1:200, Epitomics, Burlingame, CA, USA) 
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diluted in 3% BSA-TBS overnight at 4°C. After three washes of 5’ in TBS, the 
biotinylated secondary antibody (BA 1000 1:500-Vector Laboratories, Burlingame, 
CA, USA) was diluted in in blocking solution and incubated for 30’ at room 
temperature. After three washes in TBS, the slides were incubated for 30’ in with 
the ABC complex (Vectastain ABC Kit, Vector Laboratories), which was prepared 
30’ prior to use in Tris Buffer to allow complex formation. After 3 washes in TBS, the 
slides were immersed in freshly prepared DAB reagent (1mg/ml in distilled water) 
supplemented with 0.01% H202 until the signal was clearly visible on eye. Each 
section was incubated in parallel without primary antibody in order to check the 
background signal. Only the sections which did not have signal in the negative 
control were considered for the analysis. After three more washes in TBS slides 
were then counterstained in toluidine blue (1mg/ml in distilled water), which stains 
the nuclei in order to favour the perceptibility of tissue organization. Any excess of 
staining was removed by immersing the slides in a 70% ethanol supplemented with 
acetic acid solution, followed by dehydration and fixation in xylol. Slides were then 
coverslipped with Entellan (VWR, Radnor, PE, USA) and evaluated at the optical 
microscope. 
3.15 Luciferase gene reporter assay (Study I, II) 
Gene regulation can be studied with reporter assays, which permit to evaluate the 
impact of regulatory elements, on gene transcription. The regulatory elements 
include potential promoters, known promoters, partials promoters, enhancer 
elements located on the 5´untranslated region (UTR), upstream open reading 
frames (uORFs), or regulatory elements located in the 3´UTR region of their gene. 
The first step of the reporter assay consists in cloning the regulatory element into a 
vector containing the reporter gene, which encodes a protein for which the activity 
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is easily measurable (e.g. luciferase). The second step consists in the transfection 
of cells with the generated plasmid, following the detection of the expression of the 
reporter protein, which will be proportional to the activity of the regulatory region. 
Co-transfection with a plasmid constitutively expressing another protein (e.g β-Gal) 
is needed in order to normalize the variability of the results due to the efficiency of 
the transfection or differences in cell growth.  
In this case, reporter assays were performed using as the Firefly luciferase reporter 
gene, which protein emits light when its substrate luciferine is added. A simple 
representation of this principle is reported in Figure 3.4. 
 
Figure 3.4: Schematic of the luciferase reporter assay. When inserted in the cells, transcription 
of the reporter gene (luciferase) is starting under the control of the regulatory sequence (in this case 
upstream of the reporter gene). mRNA is subsequently translated into the reporter protein (Luciferase 
enzyme); by adding the substrate (luciferine) the reporter protein catalyses a reaction in which the 
light is emitted: this is the final signal that is be detected, which is proportional to the activity of the 
regulatory sequence. Adapted from https://www.thermofisher.com. 
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All the plasmids reported were kindly received as a gift, and a list of the sources is 
provided in appendix 1. 
In study I, a plasmid containing XRE upstream of the Firefly luciferase233 gene was 
used for evaluating the activity of XRE-responsive genes in relation to the 
modulation of the expression of AHRR.  
In study II, the effect of the inhibition of the activity of HSP90 was evaluated by 
reporter assays by using a plasmid containing rat-GH promoter, rat-PRL promoter, 
CRE promoter or PIT-1 promoter upstream the Firefly luciferase gene. 
A plasmid containing β-GAL gene as was used in both the studies for the 
normalization of the results. 
Briefly, 24 h before the experiment, 1X105 cells were seeded in 48-well plates. Cells 
were transfected according to manufacturer´s recommendations using 2.2 μl of 
Superfect (Qiagen) and 0.4 μg of total DNA (consisting on the reporter plasmid and 
β-Gal plasmid for normalization of the results). The day after transfection treatments 
were performed where needed and at the end of the experiment medium was 
removed and proteins were harvested in Passive Lysis Buffer (Promega). The 
protein lysate was then used for evaluating the activity of the reporter by adding the 
substrate Luciferine (p.j.k, Seoul, Korea) and luminescence indicative for luciferase 
activity was measured with the Tristar LB941 Microplate Reader (Berthold 
Technologies, Bad Wildbad, Germany). A buffer containing o-nitrophenyl-b-D-
galactopyranopside (ONPG) (Sigma-Aldrich) was added to the lysate for evaluating 
the activity of β-Gal and measurements were performed with the same microplate 
reader by reading absorbance at 595 nm wavelength. 
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3.16 Radioimmunoassay for GH and PRL (Study I, II)3. 
Radioimmunoassay (RIA) is an immunological assay for the quantification of the 
amount of antigen in a sample. The basic principle of radioimmunoassay is 
competitive binding, where a radioactive antigen named competes with a fixed 
number of antibodies or receptor binding sites. This assay has been used in study I 
for evaluating the effect on GH and PRL secretion of the silencing of AHRR and in 
study II for evaluating GH secretion in GH3 cells in response to the treatment with 
different HSP90 inhibitors.  
Cells were seeded into 96-well plates (2.0 X 103 cells/well in study I; 1.5x 104 
cells/well in study II) in DMEM 10%. After overnight recovery, the medium was 
replaced with DMEM 2% (Study I) and where needed cells were treated with HSP90 
inhibitors (Study II) for the established time. At the end of each incubation time, the 
supernatants were transferred into a 96-well plate and frozen for further analysis. At 
the end of the treatments MTT assay was performed in order to normalize GH and 
PRL secretion. Supernatants were used for RIA analysis as elsewhere reported234 
in the Clinical Neuroendocrinology Unit of Max Planck Institute for Psychiatry, 
Munich, Germany. 
3.17 Statistical analysis 
Statistical analysis was performed using the Student's t-test, Kruskall Wallis or 
Mann-Whitney tests. All tests were completed using the Statistical Product and 
Service Solutions (SPSS) software program, version 16.0 (SPSS Inc., Chicago, IL, 
USA). P<0.05 was considered as statistically significant. 
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4. Results 
4.1 Study I 
4.1.1 In vitro modulation of AHRR expression 
Stable clones were generated from GH3 in order to evaluate the effects of AHRR 
expression modulation on malignant tumor phenotypes. Two cell lines (shAHRR1 
and shAHRR2) were generated with the permanent integration in the genome of 
different shRNA sequences predicted to have at least 70% efficacy for silencing 
AHRR at transcriptional level235. A cell line with the integration in the genome of a 
scrambled sequence was established as a control (shControl). Another cell line 
(overAHRR) was created for overexpressing AHRR with the stable integration of a 
plasmid containing the gene under regulation of the constitutive promoter CMV. 
Cells with stable integration of the empty vector were used as control. AHRR 
expression in stable clones was tested at mRNA level by qPCR (figure 4.1 A, B). 
Stable AHRR-knockdown transfection showed an 81% and 70% downregulation in 
SHAHRR1 and SHAHRR2 respectively, in comparison to non-silenced shControl 
(P<0.05). Conversely, after stable AHRR-overexpression a 5.45-fold increase in 
mRNA expression was observed in comparison to control (P<0.05). Analysis of 
protein expression by western blot confirmed the qPCR results. AHRR expression 
was reduced in shAHRR1 and shAHRR2 while overAHRR showed an increased 
AHRR expression in comparison to Control (Figure 4.1 C). 
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Figure 4.1: AHRR expression of stable cell lines in the GH3 cell line. (A) Downregulation of 
AHRR mRNA expression was observed in shAHRR1 and shAHRR2 in qPCR in comparison to their 
control. (B) An increased expression of AHRR mRNA was observed in overAHRR in comparison to 
its control. Data are presented as a ratio of mRNA levels relative to the respective control and are 
represented as mean±standard deviation (SD) (n=3) with significant differences at *P<0.05. (C) 
Western blot analysis confirmed at protein level the qPCR results. GAPDH was detected as loading 
control. 
4.1.2 AHRR expression modulates AHR and XRE-responsive genes activity 
The main function of AHRR is to regulate the activity of AHR through a feedback 
negative mechanism that involves the binding on XRE sequences. (see paragraph 
1.4.2.5). In order to evaluate if AHRR expression modulation affects AHR activity, a 
luciferase reporter assay was conducted by transfecting cells with a plasmid in 
which the XRE was controlling the expression of Firefly luciferase gene. Luciferase 
experiments showed an increase in the activity of XRE in both silenced cell lines in 
comparison to shControl (1.39 and 8.11 respectively, P<0.05) ( Figure 4.2A, B); 
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conversely, a decrease in XRE activity was noticed when AHRR was overexpressed 
(0.31, P<0.05) (Figure 4. 2C). These data confirm that where AHRR is 
downregulated, it does not impede AHR binding to XRE, and transcription of XRE-
controlled genes finally increases. 
 
Figure 4.2: Effect of the modulation of AHRR expression on the activity of XRE promoter. 
Stable clones generated in GH3 cell line were transfected with plasmid containing the XRE sequence 
upstream of the coding sequence of Firefly luciferase. (A, B) Silencing of AHRR increases luciferase 
activity in comparison to the unsilenced control. (C) AHRR overexpression decreases the activity of 
XRE sequence compared to the empty vector control. Data are presented as mean ± SD in a 
representative experiment (n=2). *=P<0.05. 
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4.1.3 AHRR expression influences tumor growth potential in vitro 
MTT assay was performed for evaluating in stable clones the effect of the 
modulation of AHRR expression on cell viability. AHRR downregulation resulted in 
reduced cell growth potential. After a 96 h-time course assay, shAHRR1 and 
shAHRR2 showed a decrease in viability of 33% and 31% (P<0.05) respectively, 
compared to the nonsilenced shControl (Figure 4.3 A, B). Conversely, the 
overexpression of AHRR in the stable line overAHRR led to an increase in viability, 
which levels were above 61% of the respective control (Figure 4.3 C).  
 
Figure 4.3: 96h-time course MTT viability assay on stable cell lines. shAHRR1 and shAHRR2 
(A and B, dashed lines) grew slower than nonsilenced shControl (A and B continuous lines), 
respectively 31% and 33%. OverAHRR (C, dashed line) showed a 61% increase in proliferation 
compared with Control (C, continuous line). Results are representative of three independent 
experiments. Significant differences are determined by a two-tailed t-Student test (*P<0.05). 
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4.1.4 Cell cycle distribution is not altered by the modulation of AHRR 
expression 
To determine if the differences in the growth potential of the stable silenced cell lines 
could be mediated by a change in cell cycle distribution, cytofluorimetric analysis 
was performed on shAHRR1 and shAHRR2 and overAHRR, after propidium iodide 
staining. Nor the silencing of AHRR neither its overexpression showed to induce 
any shift in cell cycle distribution in comparison to the respective controls (Figure 
4.4).  
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Figure 4.4: Analysis of cell cycle distribution on stable cell lines. Flow cytometric analysis on 
propidium iodide-stained cells. The percentage of cells in different phases of the cycle are reported 
in the boxes (A, B, C on the left) and represented by histograms (A, B, C on the right). The results 
shown are representative of two independent experiments. 
4.1.5 AHRR influences resistance to apoptosis 
To determine if the modulation of AHRR expression in GH3 cells influences the 
resistance to apoptosis, caspase 3/7 activity was assayed in stable cell lines under 
basal conditions and in the presence of the apoptotic inducer camptothecin for 8 
hours. In the AHRR silenced cell line shAHRR1 caspase 3/7 activity was higher both 
in absence and in presence of the apoptotic stimulus in comparison to shControl 
(1.42-fold and 53.66-fold respectively, P<0.05) (Figure 4.1A). The effect of the 
treatment in inducing caspase 3/7 activity was higher in shAHRR1 than in shControl 
(2.48-fold, Figure 4.5D). ShAHRR2 did not display a different caspase 3/7 activity in 
comparison to its control under basal conditions, whether camptothecin induced a 
4.84-fold increase of caspase 3/7 activity in comparison to shControl (P<0.05, 
Figure 4.5B). As showed by the previous AHRR-silenced cell line, shAHRR2 
displayed a higher effect of camptothecin in increasing caspase 3/7 activity than 
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shControl (1.67-fold, Figure 4.5D). Contrary to the effect of AHRR silencing, stable 
overexpression of AHRR showed a decreased activity of caspases 3/7 that was 
similar both in presence and in absence of the apoptotic stimulus (0.6-fold, P<0.05) 
(Figure 4.5C, D).  
 
 
Figure 4.5: Effect of the modulation of AHRR expression on the resistance to apoptosis.. 
ShAHRR1 (A) and shAHRR2 (2) showed an increase in sensibility to apoptotic stimuli respectively. 
Conversely, overAHRR (C) was more resistant to apoptosis independently from the presence of the 
stimulus in comparison to Control. Data are presented as mean ± SD in a representative experiment 
(n=2). *=P<0.05. 
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4.1.6 AHRR downregulation decreases growth hormone and prolactin 
secretion  
GH and PRL secretion were evaluated in stable cell lines in order to clarify if AHRR 
expression modulation could alter hormonal secretion that is considered a pituitary 
malignant marker, together with increased proliferation and increased resistance to 
apoptosis. ShAHRR1 cells were seeded and supernatants were collected after 1h, 
6h, 24h and 48h for GH and PRL secretion quantification by RIA. shAHRR1 showed 
a decreased GH secretion compared to the control, with maximal effect reached at 
48h (Figure 4.6A). Moreover, AHRR-silenced cells showed a decrease in PRL 
secretion in all the time points in comparison to the control (Figure 4.6B).  
 
Figure 4.6: Effect of AHRR silencing on GH and PRL secretion. A time-course experiment was 
performed for quantifying GH and PRL secretion in the stable clone shAHRR1 and its respective 
control. AHRR silencing decreases GH (A) and PRL (B) production in comparison to shControl with 
maximal effect after 48h of incubation. Hormonal secretion values reported were normalized for the 
values obtained by running the MTT assay at the moment of the removal of the supernatant. Data 
are presented as mean ± SD (*=P<0.05). 
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4.1.7 Evaluation of the expression profile of AHRR in human pituitary 
adenomas  
The cohort consisted in 51 patients, 40 were diagnosed with acromegaly (35 with 
GH oversecretion, 5 with GH and PRL oversecretion), 11 with non-secreting 
adenomas; 6 normal pituitaries were tested in this study. The expression of AHRR 
was evaluated in all the patients by qPCR. Values were normalized considering one 
sample as calibrator and analyzed with the -2ΔΔCq method (see paragraph 3.8). 
Mean values among the different types of pituitary tumors are reported in table 4.1.  
 
Table 4.1: Analysis of AHRR expression in qPCR. Mean values for AHR, ARNT and AHRR 
expression (values relative to the calibrator) in normal pituitaries and different types of pituitary 
adenomas analyzed by qPCR. 
No statistical differences in expression of AHRR between acromegalic patients and 
normal pituitaries were found (ρ=0.122). By dividing the group of acromegalic 
patients in GH-secreting tumors and GH+PRL secreting tumors, GH-secreting 
tumors showed a higher expression of AHRR in comparison to normal pituitaries 
(p=0.041), whether GH+PRL tumors. No difference in AHRR expression was found 
 
Normal 
pituitary 
(n=6) 
Acromegaly (n=40) 
Non- secreting (n=11) 
GH-secreting 
(n=35) 
GH+PRL- 
secreting 
(n=5) 
AHRR 0.1±0.006 
0.53±0.72 (ACRO) 
0.22±0.18 
0.48±0.55 
(GH) 
0.63±1.15 
(GH+PRL) 
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between normal pituitaries and NFPA samples. A representative distribution of the 
results is showed in the box -plots of figure 4.8.  
 
Figure 4.8: Distribution of AHRR expression values among different types of pituitary 
adenomas. Representative boxplot showing minimum, maximum, median, average and 1st and 3rd 
quartile values for all normal pituitaries (NP), GH-secreting adenomas (GH), GH+PRL secreting 
adenomas (GH+PRL) and non-secreting adenomas (NS). GH-secreting tumors showed a higher 
expression of AHRR in comparison to normal pituitaries (*= P<0.05). 
4.1.8 Evaluation of the AHR pathway expression in relation to radiological 
and pathological parameters of aggressiveness 
The expression of AHRR was subsequently analyzed in the different types of 
pituitary adenomas for patients with available information about radiological 
parameters of aggressiveness 38,39 (Table 4.2). No correlation was found between 
AHRR expression levels and radiological aggressiveness in acromegalic and NFPA 
goups. 
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 Aggressive Non aggressive Ρ 
Acromegaly (17) 0.552±0.66 (9) 0.842±1.042 (8) 0.7 
Non-secreting (11) 0.187±0.148 (8) 0.357±0.226 (3) 0.15 
Table 4.2.: AHRR expression in radiologically aggressive and radiologically non aggressive 
pituitary tumors. Mean values relative to the calibrator and sample size of the patients with pituitary 
adenomas with or without pituitary tumor aggressiveness. 
Statistical analysis did not show any correlation between AHRR expression and 
pathological parameters of aggressiveness21(Table 4.3). No association with AHRR 
expression levels was found by comparing aggressive and non-aggressive tumors 
in acromegalic patients (p=0.261) and in patients with non-secreting pituitary 
adenomas (p=0.374).  
 Aggressive Non aggressive Ρ 
Acromegaly (12) 0.703±0.688 (6) 0.375±0.485 (6) 0.261 
Non-secreting (5) 0.263±0.275 (3) 0.060±0.028 (2) 0.374 
Table 4.3.: AHRR expression in pathologically aggressive and pathologically non aggressive 
pituitary tumors. Mean values relative to the calibrator and sample size (within brackets) of the 
patients with pituitary adenomas with or without pituitary tumor aggressiveness. 
4.2 Study II 
4.2.1 HSP90 is overexpressed in biopsy specimens of human GH-secreting 
pituitary adenomas 
The excessive expression of HSP90 has been observed in different types of cancer. 
Considering that it was recently demonstrated its role in the pathogenesis of 
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Cushing’s disease, it was hypothesized that HSP90 overexpression could be 
implicated in the pathogenesis of other hormone secreting pituitary adenomas. 
HSP90 immunohistochemical staining was analyzed in biopsy specimens of 
pituitary adenomas from acromegalic patients that had undergone transphenoidal 
surgery, using as a control normal pituitary tissue. Intense immunostaining for 
HSP90 was detected in GH-secreting adenomas from acromegalic patients (n=8/25, 
scores reported in appendix 2). A representative picture for the cytoplasmic staining 
is shown (Figure 4.9). The remaining GH-secreting adenomas which were not 
scored as positive had little or no signal specific for HSP90. Conversely, normal 
human pituitaries showed a typical morphology with only few single cells weakly 
expressing HSP90. 
 
Figure 4.9: Immunohistochemistry of HSP90 in cryosections. A representative example of a 
human GH-secreting pituitary adenoma (GH) form an acromegalic patient, and post-mortem normal 
pituitary tissue (NP) is shown. Counterstaining of nuclei was done with toluidine blue. HSP90α 
specific signal is brown (DAB). Magnification: 40X. 
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4.2.2 C-terminal inhibitors of HSP90 novobiocin and KU174 decrease the 
activity of GH-promoter 
Reporter gene assays were performed for evaluating the effect of the HSP90 
inhibitors tested on the activity of GH-promoter. GH3 cells were transiently co-
transfected with the reporter plasmid and β-gal for normalizing the results obtained. 
Figure 4.10 displays the effects of 24-hours treatment with the indicated HSP90 
inhibitors. The N-terminal inhibitor 17AAG did not decrease the activity of the GH 
promoter. Conversely, treatment with the C-terminal inhibitor of HSP90 novobiocin 
decreases in a dose-dependent way the activity of the GH-promoter with maximal 
luciferase inhibition at the 100 μM concentration (50%, P<0.05). KU174 resulted to 
be more efficacious in decreasing the activity of GH-promoter, with maximal 
luciferase inhibition at 4μM (77%, P<0.05). 
 
Figure 4.10: Determination of GH-promoter activity in GH3 cells using reporter gene assay. 
Effect of 24h treatment with the N-terminal inhibitor 17-AAG and the C-terminal inhibitors novobiocin 
and KU174 on GH-promoter activity. Values are represented in comparison to the untreated control. 
Means ± SD of one representative experiment are shown (n=3, *P<0.05). 
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4.2.3 The C-terminal inhibition of HSP90 KU174 decreases growth hormone 
secretion in a cellular model of somato-lactotroph pituitary adenoma 
In order to investigate the downstream effects of HSP90 inhibition GH3 cells were 
treated for 24 h with increasing concentrations of 17 AAG, novobiocin and KU174 
and supernatants were collected and GH was quantified by RIA. The C-terminal 
inhibitor KU174 decreased GH secretion levels in a dose-dependent way, being 
both effective at 2μM (28%, P<0.05) and 4 μM (54%, P<0.05) (Figure 4.11). 
 
Figure 4.11: Evaluation of the effect of HSP90 N-and C-terminal inhibitors on GH-secretion in 
GH3 cells. Cells were treated for 24h treatment with the N-terminal inhibitor 17-AAG or one of the 
C-terminal inhibitors novobiocin and KU174. Values are represented in comparison to the untreated 
control. Means ± SD. of one representative experiment are shown (n=3, *P<0.05). 
4.2.4 C-terminal inhibition of HSP90 with KU174 decreases the promoter 
activity of PIT-1 and CRE 
The second reporter assay was performed for testing the effect of HSP90 inhibition 
on the activity of promoters of genes primarily involved in the GH signaling: CREB 
(cAMP response element-binding protein, a cAMP-responsive transcription factor 
regulating the somatostatin gene) and PIT-1 (pituitary-specific transcription factor 1, 
responsible for pituitary development and hormone expression in mammals). GH3 
 89  
 
cells were transiently co-transfected with the reporter plasmids and the β-Gal for 
normalization. Figure 4.12 shows the effect of 6h treatment with the HSP90 C-
terminal inhibitor KU174. Consistent with the previously reported results, the drug 
showed a dose-response effect in decreasing the activity of both promoters in 
precence of forskolin (FSK) 10 μM. 
 
Figure 4.12: Determination of CRE-and PIT-1-promoter activity in GH3 cells using reporter 
gene assay. Cells were treated with the C-terminal inhibitor KU174 (in presence of 10 μM forskolin). 
The activity of CRE-and PIT-1 promoters was evaluated after 6h of incubation. Values are 
represented in comparison to the untreated control. Means ± SD of one representative experiment 
are shown (n=3, *P<0.05). 
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4.2.5 Exposure of GH3 cells to KU174 results in downregulation of Akt, 
CREB and Pit-1 expression 
The effect of KU174 on the expression of client proteins of HSP90 and pituitary 
tumor-related proteins was subsequently examined by western immunoblotting 
(Figure 5) in absence and in presence of 10μM forskolin stimulation. 48h incubation 
with KU174 at 4 μM concentration in absence of forskolin stimulation (0h) resulted 
in a 60% decrease in the expression of Akt (Figure 5B), which is known to be direct 
interactor of HSP90 and is involved in the activation of CREB protein 180. A 
progressive decrease of total CREB expression was registered during the treatment 
with forskolin with minimal expression after 6h stimulation with forskolin (53% 
compared to stimulated control, Figure 5C). No increase in HSF-1 expression was 
reported after during the treatment KU174 as a proof of the absence of the induction 
of a stress response (Figure 5D).  
 
 91  
 
 
Figure 5: Immunoblot representing the treatment with KU174 and after 1h, 3h and 6h co-
treatment with forskolin in GH3 cells. (a) Cells were initially treated for 48h with KU174 (4μM) and 
then stimulated for 6h with forskolin 10 μM for evaluating the effect of the C-terminal inhibition of 
HSP90. Actin was used as loading control. (b) Quantification of Akt protein expression after 48h 
treatment with KU174 4μM; (c) Quantification of total CREB expression after treatment with KU174 
4μM and final 6h stimulation with forskolin 10 μM; (d) Quantification of HSF1 expression after 48h 
treatment with KU174 4μM. 
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5. Discussion 
5.1 Study I 
Several aspects about pituitary tumorigenesis still need to be understood, especially 
the factors determining the particular benign and slow–growing nature of these 
tumors; some answers to these questions could be found through the analysis of 
novel molecular pathways which have been recently considered. 
AHR pathway has been recently hypothesized to play a role in pituitary 
tumorigenesis. In fact, different studies proved the relation between AHR and the 
modulation of the pituitary function135,136,140,142, and its correlation with pituitary 
tumor aggressiveness or a more severe disease140,142. However, still little is known 
about the role of AHRR in the pituitary, apart from the demonstration of its activation 
after the stimulation of AHR activation, confirming the existence of a functional 
feedback mechanism of regulation of this pathway in vivo and in vitro158,159. 
Considering the few studies reported in literature which proposed AHRR as new 
candidate TSG160–162, and the presence of AHRR overexpression reported in 
somatotropinomas163, the main focus of this study was to investigate its possible 
role in pituitary tumorigenesis. Stable cell lines were generated for AHRR silencing 
or overexpression. The analysis of the XRE reporter activity proved that the 
modulation of the expression of AHRR potentially influenced the activity of XRE 
responsive genes, giving an indirect proof of a functional feedback mechanism of 
regulation of AHR activity and AHR-related genes, in accordance with previous 
studies 158,159. In addition, the differential expression of AHRR showed decreased 
growth potential, whether AHRR overexpression displayed the opposite effect. The 
MTT results were confirmed by cell counting (Trypan blue staining, data not 
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reported). These findings could reflect cell- or adenoma/carcinoma context or tissue-
dependent differences in the overall activity of the AHR signaling, including AHRR 
behavior. To support the fact that AHR-AHRR signaling acts in a tissue dependent 
manner and that specifically in pituitary AHR activation seems to be correlated with 
a milder malignant phenotype, treatment with curcumin, and indirect activator of 
AHR236, displayed antiproliferative effect in pituitary adenomas both in vitro and in 
vivo237. In a recent report by Formosa et Al. in 2015, AHR overexpression in the 
GH3 cell line and activation with BαP reduced cell proliferation, which is accordance 
to the effect on proliferation of the modulation of AHRR expression238.  
AHRR silencing in stable cell lines led to a decreased resistance to the treatment 
with the apoptosis inducer camptothecin in comparison to the control; conversely, 
AHRR overexpression showed an increased resistance to the same stimulus. These 
data provide another proof of the fact that the modulation of the regulation of the 
AHR-AHRR pathway influences the aggressiveness of the tumor phenotype, as 
already reported in in vitro studies140,237,239. 
Due to the interesting results that suggested a role of AHRR in regulating commonly 
considered hallmarks of tumor activity (cell proliferation and apoptosis), the impact 
of AHRR silencing in hormone secretion has been further investigated. Considering 
that GH3 cells are a model for GH- and PRL- secreting pituitary adenomas, the 
secretory activity of both hormones has been evaluated. As a result of AHRR 
silencing, cells reduced the secretion of GH and PRL in comparison of control. 
These results are apparently in contrast with the first reported evidence of Elango 
et al., 2006 in which the modulation of pituitary function by TCDD in rainbow trout 
pituitary was investigated, and AHR activation led to an increase of GH and PRL 
mRNA expression. However, this study also reported a suppression of GH and PRL 
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expression at very low doses of TCDD in the pM range135. Partially in accordance 
to this study, a more recent study by Moran et Al. in 2012 displayed that co-treatment 
of GH3 cells with βNF and αNF (which is supposed to have opposite effects of βNF 
) displayed PRL gene suppression, with little or no effect on GH gene expression136. 
Although the decrease of GH and PRL secretion reported in this study might support 
the hypothesis that of AHRR silencing may mitigate tumor phenotype of GH- and 
PRL- secreting adenomas, further evaluations are needed to finely understand the 
molecular pathways involved in this phenomenon. Even in presence of a possible 
involvement of XRE-responsive genes modulation demonstrated by reporter 
experiments in GH3 cells, it is still unclear if the decrease in GH/PRL secretion in 
AHRR silenced cells is directly mediated by AHRR-AHR signaling or if it involved 
AHR independent pathways. 
In addition, cellular senescence has been evaluated for its possible contribute to the 
slow growing phenotype of AHRR silenced cell lines. Senescence could partially 
explain the peculiar behavior of pituitary tumors, which usually are benign present 
a very slow growth rate 96. In fact, it is consolidated that cellular senescence 
represents an important protection against malignancy73. ShAHHR1 showed an 
intense SA-β Gal staining in comparison to the non-silenced control, in accordance 
to the lower proliferation rate reported in AHRR-silenced stable cell lines. However, 
no variations in cell cycle population were found. This result could be partially 
explained by an uncoupling between cell cycle arrest and the manifestation of 
cellular senescence due to some molecular mechanisms independent from Cdk 
activity240. 
The aim of the final part of this study was to investigate possible correlation between 
pituitary adenoma aggressiveness and AHRR expression in acromegalic and 
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NFPAs patients. Consistent with previous findings, AHRR was overexpressed in 
patients with GH- secreting pituitary adenomas in comparison to normal 
pituitaries163, whether no differences were found in AHRR expression between 
prolactinomas and NFPAs in comparison to normal pituitaries. Due to the lack of a 
clear consensus for the determination of the aggressiveness of pituitary adenomas, 
tumor aggressiveness was evaluated in the analyzed cohort analyzed referring to 
the available data regarding pathological aggressiveness (MIB-1 and p53 IHC 
staining) or radiological aggressiveness (invasion by the tumor of the surrounding 
anatomical structures). No correlation was found in the selected cohort between 
AHRR expression and the presence of aggressiveness markers. Moreover, is 
important to consider that just few data were available regarding tumor 
aggressiveness in the analyzed cohort, therefore increasing the sample size could 
improve the consistency of this analysis. Finally, the possible problem of the cellular 
heterogeneity of surgical specimens could be partially overcome by IHC analysis, 
which can detect the expression of AHR-AHRR directly on tumor cells. This study is 
actually ongoing but results are still too preliminary to be discussed herein. 
In conclusion, these results provide the demonstration of a putative oncogenic role 
of AHRR in the GH3 cell line model used by affecting AHR activity. Further 
evaluations are needed to clarify the molecular mechanisms behind the presence 
of a senescent phenotype due to AHRR silencing and to confirm the findings 
observed in the cellular model in human pituitary adenomas. 
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5.1 Study 2 
Increased chaperone expression of the proteins belonging to the HSP family 
contributes to oncogenesis at several levels170. In particular, a constitutive and 2-
10-fold higher HSP90 expression was reported in various tumor cells in comparison 
to their normal counterparts, which means that its function must be important for 
growth and survival of tumor cells176,186. Therefore, greater attention has been put 
to HSP90 as a possible therapeutic target, and several inhibitors have been 
designed with promising results in different types of tumors. Recently, the role of 
HSP90 in ACTH-secreting tumors has been investigated by Riebold et al., 2015. 
The authors found that HSP90 is overexpressed in corticotroh adenomas in 
comparison to the normal pituitary, and treatment with C-terminal inhibitors of 
HSP90, especially silibinin, showed an impressive therapeutic efficacy with a partial 
recovery of the glucocorticoid sensitivity177. Based on these findings, aim of this 
study was to clarify if HSP90 could be implicated also in the pathogenesis of GH-
secreting pituitary tumors. IHC analysis of GH-secreting tumors displayed 
overexpression of HSP90 in 8/25 patients. This result gives some support to the 
hypothesis that HSP90 expression could be one of the possible mechanisms that 
drive the pathogenesis of GH-secreting pituitary adenomas. Subsequently, the 
therapeutic effect of N- and C-terminal inhibitors of HSP90 was tested by using the 
GH3 cell line as a model. The effect of the different inhibitors on the activity of the 
GH promoter was tested. The C-terminal inhibitors novobiocin and KU174 
decreased GH-promoter activity in a dose-dependent manner. The effect of KU174 
was more pronounced, due to the fact that this compound is an improved analogue 
of the novobiocin 218. Conversely, the N-terminal inhibitor 17-AAG increased the 
transcriptional activity of GH, suggesting a different effect mechanism of action on 
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client proteins possibly due to the inhibition of the N-terminal domain. GH secretion 
quantification of GH3 cells after the treatment with HSP90 inhibitors confirmed the 
effects observed at transcriptional level: only KU174 is able to decrease GH 
secretion in a dose-dependent way, while novobiocin and 17-AAG did not lower GH. 
While the lack of effect of 17-AAG could be interpreted as the lack of effect in GH-
secreting pituitary tumors, the absence of a suppressive effect of novobiocin could 
be due to its reduced potency for inhibiting HSP90 in comparison to KU174218. 
Due to these promising results regarding the efficacy of KU174 in terms of GH 
production and secretion, the molecular mechanisms that could be involved in 
HSP90 inhibition have been assayed. The effect of HSP90 inhibition has been 
tested in relation to the activity of CRE- and PIT-1 promoters, which play a pivotal 
role in controlling the expression of human and rat GH genes11. CRE is a cAMP 
response elements present on the human GH promoter. CRE is normally target of 
the proteins related to the cAMP-response element binding protein 
(CREB)/activating transcription factor-I (ATF-1). After the stimulation with forskolin, 
which mimicked the the cAMP increase induced by the stimulation of GHRH, a dose-
response decrease in the activity of CRE promoter was reported. This result 
suggests a role of the inhibition of HSP90 by KU174 in controlling the response to 
high cAMP levels, possibly due to the lack of stabilization of client proteins involved 
in the cAMP pathway that are interacting with a functional HSP90.  
PIT-1 is a pituitary-specific transcription factor regulating the expression of both rat 
and human GH genes through the binding to its specific sites in the GH promoter 
region11,12. After the stimulation of the cAMP pathway, a dose-response suppressive 
effect of the activity of the promoter by KU174 was observed, suggesting that the 
overall efficacy of the compound could be due to a pituitary-specific effect. Western 
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blot analysis was then performed in order to verify if these findings could be 
correlated to protein degradation of pituitary-specific markers and HSP90 
interactors. Although no clear effect was observed regarding the amount pf 
phosphorylated CREB, there was a clear decrease in total CREB expression, which 
could suggest the degradation of the total protein due to the inhibition of the activity 
of HSP90. Moreover, A decrease expression of Akt protein was also observed, 
which is a known interactor of HSP90. These two findings could be correlated by 
the fact that CREB could be a downstream target of the HSP90/Akt signaling, so 
that the inhibition of the activity of HSP90 could have an impact on CREB expression 
or stability241,242. Another important finding to consider is that the C-terminal inhibitor 
KU174 exerted its effect without eliciting a heat shock response because no 
increase in HSF-1 was encountered. This particular aspect was already reported in 
a previous study in prostate cancer and could partially explain the reason why C-
terminal inhibitors of HSP90 showed a better efficacy in comparison to the N-
terminal counterparts216,218,243. 
In conclusion, thanks to the promising effects demonstrated by KU174, this study 
provides the rationale for permitting further investigations on HSP90 as a target for 
the therapeutic management of GH-secreting tumors. Moreover, it confirms the 
biological differences already reported in several studies between N- and C-terminal 
inhibitors of the HSP90, possibly due to the degradation of a different battery of 
interactors or co-chaperones including the differential effects on HSF-1, which 
activation with N-terminal inhibitors drives the induction of a heat shock response. 
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Appendix 1 
List of plasmids used in this thesis. 
Plasmid Source/ Kind gift of 
shAHRR1 SABiosciences, Frederick, MD, USA 
shAHRR2 SABiosciences, Frederick, MD, USA 
shControl SABiosciences, Frederick, MD, USA 
overAHRR ORIgene, Rockville, MD, USA 
Control ORIgene, Rockville, MD, USA 
XRE-luc Xavier Coumoul, Univ. Paris Descartes, France 
rGH-luc Guiterrez-Hartmann, University of Colorado, USA 
CRE-luc Clontech Laboratories Inc., Palo Alto, CA, USA 
PIT-1-luc C. Alvarez, Univ. of Santiago de Compostela, Spain 
β-Gal D. Spengler, MPI of Psychiatry, Germany 
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Appendix 2 
IHC staining score of the cohort of GH_secreting pituitary adenomas analysed. -= no 
expression; +/-= low expression; += medium/high expression; ++= high expression 
Sample Score 
1 +/- 
2 +/- 
3 ++ 
4 +/- 
5 +/- 
6 +/- 
7 +/- 
8 +/- 
9 - 
10 + 
11 + 
12 + 
13 ++ 
14 + 
15 + 
16 +/- 
17 +/- 
18 - 
19 - 
20 + 
21 +/- 
22 +/- 
23 +/- 
24 -+/- 
25 -+/- 
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